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Abstract 
Prostate cancer is a significant disease affecting most men as they age. Although the 
overall lifetime mortality from the disease is about 3% the disease has a high 
prevalence and the treatment for the disease carries with it unwanted morbidity. Our 
group has shown that plexin B1 protein expression is elevated in prostate cancer and 
have suggested a link with metastatic prostate cancer.  
 
The mechanism for the increased expression of plexin B1 in prostate cancer is 
unknown, the aim of this study was to elucidate the cause for this upregulation. I 
hypothesized that microRNAs are linked with the increased expression of plexin B1, 
either through loss of miRNA binding sites in the 3’UTR of plexinB1 mRNA or through 
loss of specific miRNAs that regulate plexinB1 expression. I found no evidence for 
plexinB1 mRNA variants with truncated 3’UTR resistant to miRNA down regulation. Two 
splice variants were identified in prostate cancer cells that are predicted to alter 
plexinB1 function, one being variant R hitherto unproven in literature. I performed an 
insilico and an in vitro functional screen to identify candidate miRNAs that regulate 
plexinB1 expression. The candidate miRNAs were then assessed to establish if they 
directly bound to the 3’UTR of plexinB1 and regulated expression of a reporter gene 
and to determine if they had any effect on endogenous plexinB1 mRNA and protein 
levels in prostate cancer cell lines. MiRNAs 199a and miRNA 214-3p reduced 
expression of the reporter gene and endogenous plexinB1, suggesting that these 
miRNAs negatively regulate plexinB1 expression directly by binding to the 3’UTR of 
plexinB1. MiRNA 1 was found to down regulate endogenous plexinB1 expression 
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probably indirectly. I conclude that there is a role for specific microRNAs in regulating 
plexin B1 expression with potential for prostate cancer therapy but further studies are 
needed to validate my findings.
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Plexins and Semaphorins Overview 
 
The Semaphorin-Plexin signalling pathway is responsible for many normal functions in 
the body such as the embryological development of the nervous, cardiovascular and 
skeletal systems (Perala et al., 2012). This pathway is involved in the immune system 
as well as in tumour progression. This section aims to summarise what is known about 
the structure of Semaphorins and Plexins and also their normal functions. 
 
Semaphorins 
Semaphorins (Sema) belong to a super family of over 30 proteins found mainly in 
multicellular organisms (Potiron et al., 2009). There are 8 classes within the semaphorin 
family and they consist of 21 vertebrate genes and 8 invertebrates genes (Neufeld and 
Kessler, 2008). The 8 classes are shown in figure 1 below. 
 
Classes 1 and 2 are invertebrate Semaphorins, while 3 to 7 represent the vertebrates 
and class 5 comprises both invertebrate and vertebrate Semaphorins, finally class V are 
the viral semaphorins (Perala et al., 2012). The Semaphorins are mainly known for their 
role in the nervous system, but they are expressed in various other tissues and organs 
including renal, cardiac, endocrine, gastrointestinal and seem to be expressed more in 
the developmental stages in humans and wane with age (Yazdani and Terman, 2006). 
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Fig 1 modified from Neufeld and Kessler  (Neufeld, G. and O. Kessler 2008) 
Diagram of the Semaphorins, with their receptors Plexins and Neuropilins. 
 
 
Fig 1a: The 8 classes of semaphorin showing their subunits and domains and 
relationship with the cell wall. 
Fig 1b: Plexins, showing their subunits and domains. 
 
Structure and functions of the domains of Semaphorins 
Semaphorins are homodimers composed of paired identical polypeptide chains. They 
have a characteristic feature, the Semaphorin domain that contains approximately 500 
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amino-acids. This domain also occurs in the Plexins and Met families (Potiron et al., 
2009). This Sema domain is essential for semaphorin signaling and it is through the 
analysis of the X-ray structure of the Sema domains of Semaphorin 3D and Semaphorin 
4D that it is known that this segment is a conserved seven blade beta propeller 
structure (Neufeld and Kessler, 2008, Yazdani and Terman, 2006).  The seven bladed 
structure of the Sema domain, which is seen in other proteins, is the largest of its kind 
due to the number of amino acids present (Gherardi et al., 2004). It is given the name 
due to the similarity to a propeller with its multi-stranded beta sheets that surround a 
central axis, see figure 2.  
 
Fig 2 Schematic diagram of the propellar blade structure of the SEMA domain 
 
The Sema domain is the region where most of the interactions occur between 
semaphorin and other proteins that lead to signaling effects. For instance the sema-
18 
 
sema interaction of the blades of the propeller structure of semaphorin and that of the 
plexins (Yazdani and Terman, 2006, Gherardi et al., 2004, Sakurai et al., 2012) 
 
There is a conserved stretch of 54 amino-acids that occurs after the carboxy-terminal of 
the sema domain that bears homology to the N-terminal of the same region of beta 
integrins and is designated the PSI (Plexin-Semaphorin-Integrin) domain. Its role is to 
correctly orient semaphorin with its receptor, but it may also be involved in signaling as  
the PSI domain of β 1 integrins binds to antibodies (Hota and Buck, 2012, Kozlov et al., 
2004). Only the viral Semaphorin V lacks the PSI domain. Another recurrent domain in 
the Semaphorins is the immunoglobulin-type domain, whose function is to enhance the 
effect of the Sema domain (Yazdani and Terman, 2006), see figure 1.   
 
Semaphorins diverge in their C-termini and can be either transmembrane, anchored into 
the plasma membrane or secreted. Class 3 Semaphorins are the only secreted 
vertebrate Semaphorins and are distinguished by the presence of a conserved basic 
domain at their C- termini. Classes 4 to 7 are all cell membrane anchored proteins. 
There are structures that differentiate each class, such as thrombospondin repeats 
which are peculiar to class 5. The thrombospondin repeat domain in Sema 5A has been 
shown to regulate Sema5A axon guidance cues by forming links with proteoglycans 
(Kantor et al., 2004). Class 7 have a GPI anchor that holds them to the cell wall 
(Neufeld and Kessler, 2008). 
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Plexins 
Plexins are the primary receptors of Semaphorins. They are a large family of trans-
membrane glycoproteins. The first Plexin molecule was discovered in the African 
clawed frog xenopus laevis using an antibody produced from plexiform layers of its optic 
tectum, hence the name Plexin (Takagi et al., 1987) . Like Semaphorins, Plexins are 
widely expressed in nervous and other tissues in the body.  
 
Structure 
The nine vertebrate Plexins are divided into 4 subfamilies as follows;  
4 in type A (A1, A2, A3 and A4)  
3 in type B (B1, B2 and B3) 
1 in type C (C1) 
1 in type D (D1)  
 
Plexins have a characteristic split GTPase-activation protein (GAP) cytoplasmic domain 
and are the only known membrane spanning receptors that interact directly with small 
intracellular GTPases (Neufeld and Kessler, 2008). Their role will be discussed later. 
Diagrams of the Plexins are shown in figure 1. 
The extracellular domain of all Plexins is distinguished by the Sema domain, the 
presence of PSI and glycine-proline (G-P) rich motifs that the plexins share with tyrosine 
kinase receptors belonging to the Met family. The Plexin B family contains in addition a 
C-terminal binding site for the PDZ domain containing GEF (PDZ-RHOGEF) and LARG 
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and in their extracellular domain a conserved cleavage site for furin-like proprotein 
convertases that is not found in other Plexins. Plexin B1 is of a particular interest 
because of the link with prostate cancer as highlighted by Wong et al(Wong et al., 
2007), this will be discussed in detail later.  
 
The variants of Plexin B1  
The human Plexin B1 gene is found on Chromosome 3 p21 and it has 37 exons and 
composed of over 26,000 nucleotide bases. One of the key steps in the process that 
leads to protein production is the transcription of genes in DNA to RNA. The DNA is first 
transcribed to precursor messenger RNA (pre-mRNA) in the nucleus following which 
splicing occurs to remove the intervening sequences (introns)(Black, 2003). This results 
in mature mRNA containing only exons. This is termed constitutive splicing and is the 
conventional form of splicing. Splicing is catalysed by Spliceosomes which are 
macromolecular complexes. Other events that occur post transcription within the 
nucleus include 5’ capping and 3’ polyadenylation(Hui, 2009). There are two main forms 
of the Plexin B1 mRNA produced by constitutive splicing as listed below(NCBI, 2011);  
Variant 1(NM002673)  
 Variant 2 (NM001130082)  
The variants 1 and 2 mRNA are similar but differ in the 5’ UTR region of the mRNA, 
they code for the exactly the same full length plexin B1 protein with 2135 amino acids.  
This full length is a single pass transmembrane receptor. A breakdown of the 2135 
amino acid is as follows: The extracellular domain (ECD) is composed of type 1 
transmembrane glycoprotein that contains 1471 aminoacids. This ECD contains the 
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semaphoring domain, three PSI domains, and three IPT repeats. The cytoplasmic 
region or domain (CD) contains 612 aminoacids. The schematic diagram of the protein 
is shown in figure 3 below. 
 
Fig 3: Schematic diagram of protein for variant 1 and 2  courtesy of_plasma proteome 
database 
 
 
(SEMA- Semaphorin domain; PSI- Plexins, semaphorins, integrins domain; IPT- Immunoglobulin-like Plexin 
Transcription factors domain) 
 
There is another form of splicing termed alternative splicing that leads to the formation 
of other variants of mRNA. Alternative splicing allows multiple proteins to be produced 
from a single gene. This occurs at precursor mRNA (pre-mRNA) level(Hui, 2009). 
Alternative splicing accounts for the hundreds of thousands of proteins produced by 
humans, despite an estimated 20,000 to 25,000 coding genes (Hui, 2009, 2004). 
Alternative splicing occurs due to the following four main methods; a) Cassetted exon 
skipping or inclusion; b) alternative 5’ splice sites; c) alternative 3’ splice sites; d) intron 
inclusion(Nilsen and Graveley, 2010). This means that one gene may produce a variety 
of different mature mRNAs and therefore proteins termed alternatively spliced variant 
proteins. This phenomenon of alternative splicing was first discovered by Berget et al 
with their work on the viral hexon mRNA in 1977(Berget et al., 1977). There is a 
22 
 
correlation between the complexity of the organism and the occurence of alternative 
splicing, with more complex organisms having a greater proportion of their genes 
undergoing alternative splicing(McManus and Graveley, 2011). 
 
In the case of Plexin B1gene, alternative splicing online human databases have shown 
up to 21 possible different alternatively spliced mRNA variants out of which only 5 
produce a form of the Plexin B1 protein(Project, 2011, NCBI, 2011, Ensembl, 2011). 
The two most common forms of alternatively spliced variants of Plexin B1 mRNA 
according to the online databases are: 
 Truncated variant ‘AJ011414’ 
 Variant R ‘AJ011415’ 
The truncated variant has a significantly shorter 3’ UTR end, it is the shorter of the two 
presumably because it has a different polyadenylation signal site closer to the 5’ end of 
the mRNA. Its mechanism of alternative splicing includes an exon skipping, it doesn’t 
have the exon 11. The splicing out of exon 11 in this variant results in a shift in the 
reading frame. Translation of the mRNA is terminated prematurely due to the presence 
of a stop codon in the new frame. The protein product of this mRNA does not contain 
the inter-membranous or cytoplasmic component unlike the full protein. The protein of 
the truncated variant contains only 729 amino acids (NCBI, 2011, Tamagnone et al., 
1999). The truncated variant as shown in the figure 4 below only has two PSI domains 
and lacks the transmembranous and cytoplasmic domains therefore it is a secreted 
form of the protein. Variant R is the longer of the two alternatively spliced variants and 
one of its modes of formation is also exon 11 skipping. Variant R also appears to have a 
23 
 
shortened 3’ UTR end but not to the same extent as the truncated variant.  It is similar 
to the full length mRNA of Plexin B1 and its protein contains 1952 amino acids(NCBI, 
2011, Tamagnone et al., 1999). A summary of the common variants of plexin B1 are 
shown in table 1 below. 
Fig 4: Schematic diagram of protein for variant R and Truncated variant courtesy 
of_plasma proteome database 
 
Protein- variant R (AJ011415) 
 
 
Protein- truncated Variant (AJ011414) 
(SEMA- Semaphorin domain; PSI- Plexins, semaphorins, integrins domain; IPT- Immunoglobulin-like Plexin 
Transcription factors domain) 
 
Table 1: The common variants of plexin B1 
 
                                      The common variants of Plexin B1 
Constitutively spliced  Alternatively spliced 
Variant 1 ‘NM002673’ (7325bp) 
Variant 2 ‘NM001130082.1’ (7158bp) 
Variant R ‘AJ011515’ (5859bp) 
Truncated variant ‘AJ011414’ 
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The Semaphorin signalling pathway 
Semaphorin binds to Plexin to activate a signalling pathway. Upon activating the 
signalling pathway changes occur within the cytoskeleton which causes cellular 
movement and changes in morphology, such as axonal retraction (Kruger et al., 2005). 
 
The semaphorin signaling pathway involves the interaction of various proteins with the 
extracellular and intracellular regions of Plexins. The extracellular interactions are the 
start of the signalling pathway that continues downstream into the cell. For example 
neuropilins, which are essential co-receptors to Sema 3s which do not bind directly to 
Plexin, true for all SEMA 3 ligands the exception being SEMA3E (Capparuccia and 
Tamagnone, 2009);  Offtrack (OTK) a receptor tyrosine kinase which combines with 
Sema 1a and Plexin A leading to axonal repulsion; CD72 and Tim 2 which are receptors 
to the Sema 4s involved in immune response; Also Sema 4 interacts with Met and  
ErbB2 through Plexin B1(Zhou et al., 2008). 
The various Semaphorins require specific Plexin receptors to function. Sometimes the 
same Plexin acts as a receptor for different Semaphorins. Examples of these are listed 
in table 2 below; 
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Table 2: The interactions of the Semaphorins and their receptors 
Semaphorin Receptor –Plexins ( others) 
1A,1B A 
2A B 
3A,3B,C,D,F A (with neuropilin co-
receptor) 
3E D 
4A (Tim-2) 
4D B1 
5A B3 
6A,6B A4 
7 C1 
V C1 
 
Figure 5 shows a broader example of the Semaphorins and their receptors involved in 
signal transduction.   
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Fig 5 courtesy of Neufeld and Kessler (Neufeld, G. and O. Kessler 2008) 
The Interactions of semaphorins with its receptors 
 
 
The signalling pathway also involves a variety of intracellular components.  Some 
examples of the signaling pathways are listed below, focusing on Sema4D and its main 
receptor Plexin B1; 
 a) The GTPases  
 b) The receptor tyrosine kinases.  
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A) The GTPases- 
1.The R-Ras   
Sema 4D binds to Plexin B1 to activate the R-Ras GTPase activation protein (GAP) 
domain activity of Plexin B1, see figure 6. The stimulation of the GAP domain is also 
dependent on RND1 binding to the intracellular region of Plexin B1which then allows 
Plexin B1 to act on R-Ras, converting it to R-Ras GDP from R-Ras GTP(Pasterkamp, 
2005, Kruger et al., 2005).  R-Ras regulates integrin activity, causing integrin mediated 
cell adhesion to the extracellular matrix.  When Sema 4D binds to Plexin B1 the effect is 
to decrease activated R-Ras leading to reduced cellular adhesion to the extracellular 
matrix and detachment of the cells. This was proven by experiments involving the 
mutated forms of Plexin B1 that were unable to interact with R-Ras or RND1 resulting in 
unchanged level of GTP bound R-Ras. Integrins are involved in intracellular pathways 
which lead to important functions like cell death and movement. Thus there is inhibition 
of integrin activities, such as directional migration of cells leading instead to retraction.   
Figure 6:The Sema4D-Plexin B1 pathway involving R-Ras 
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2. Rac 
 Another GTPase involved in the signaling pathway is Rac. Rac binds to an intracellular 
region of Plexin B1 (figure 7). Binding leads to the sequestering of Rac, which in turn 
reduces the amount of free active Rac in the cytoplasm. Rac activates p21-activated 
kinase, which polymerises actin. So there is inhibition of p21- activated kinase (PAK). 
The final result is to inhibit cellular actin polymerization and lamellipodia therefore 
causing repulsion (Wannemacher et al., 2011, Kruger et al., 2005). 
Figure 7 
The Sema4D-Plexin B1 pathway involving Rac 
 
 
3. RhoA 
 The intracellular C terminal PDZ-binding region of Plexin B1 binds to the Rho specific 
guanine nucleotide exchange factors (RhoGEFs) (Kruger et al., 2005, Ch'ng and 
Kumanogoh, 2010). RhoA activation leads to repulsive growth of nerve cells due to the 
formation of stress fibres that cause contraction within the cytoplasm. The activation of 
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RhoA occurs through the Sema 4D-Plexin B1 signalling pathway. After Sema 4D binds 
to Plexin B1 the PDZ domain of Plexin B1 stimulates the RhoAGEFs LARG (Leukaemia 
associated RhoGEF) and PDZ-RhoGEF to cause the conversion of RhoA-GDP to 
activated RhoA-GTP, see figure 8.    
 
Figure 8 
The Sema4D-Plexin B1 pathway involving Rho 
 
4Rnd 
Rnd1 is another member of the Rho family. It has been shown to cause contraction or 
shrinkage of cells by Oinuma et al (Oinuma et al., 2003) interacting directly with plexin 
B1 in the presence of Sema 4D  
 
5Rap 
Plexins also act as GAPs for Rap (Wang et al., 2012) 
30 
 
 
B) The Receptor Tyrosine Kinases (RTK) 
The binding of Sema 4D to Plexin B1 also stimulates the tyrosine kinase activity of Met 
and ErbB2 leading to cell migration (Zhou et al., 2008).  Met or ErbB2 binds to the 
extracellular region of Plexin B1 in the presence of bound Sema 4D which causes the 
phosphorylation of Met or ErbB2 and Plexin B1.  
 
Figure 9 
The Sema4D-Plexin B1 pathway involving Met or ErbB2 
 
 
 
To summarise the different interactions with plexin B1 causes a number of action within 
the cell that is shown in the schematic diagram in figure 10 below.  
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Figure 10 
A Schematic diagram of Plexin B1 function   
 
Functions of the Semaphorin-Plexin pathway 
The Semaphorins are present in many tissues of the body. The semaphorin-plexin 
pathway is involved in organogenesis, angiogenesis, Immunity and in tumour 
progression. 
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Semaphorin 4D  
Immunity: SEMA4D was the first semaphorin identified in the immune system. SEMA4D 
(also called CD100) activates B cells in the immune system, increasing the quantity of B 
cells and antibody production. SEMA4D is expressed at high levels in tissues such as 
those of the spleen and the thymus. It is expressed in high levels on T cells, and in 
lower levels in B cells and macrophages. Its receptors include Plexin B1 and CD72 
(Ch'ng and Kumanogoh, 2010, Nkyimbeng-Takwi and Chapoval, 2011). Plexin B1 is 
mainly found in epithelial and endothelial cells such as in the kidney, prostate and 
digestive tract among others. In the immune system Plexin B1 is expressed on the 
surface of dendritic cells (DC) and activated T cells. Several studies have shown the 
effect of SEMA4D through Plexin B1 is to increase B cell and DC activity, for instance B 
cell proliferation in mice(Nkyimbeng-Takwi and Chapoval, 2011). CD72 on the other 
hand is found mainly on the surface of B cells and in lower quantity on macrophages.  It 
has a negative signalling effect on these cells, these signals are switched off by 
SEMA4D after binding.  The intracellular region of the CD72 contains a tyrosine based 
domain ITIM that binds to tyrosine phosphatase SHP1, this SHP1 is released once 
SEMA4D binds to CD72 allowing the activation of B cells.    
 
Angiogenesis: Angiogenesis is the creation of new blood vessels and is promoted by 
the Semaphorin-Plexin pathway. For instance in-vitro studies have shown the 
proangiogenic effects of the Semaphorin 4D and Plexin B1 interaction (Perala et al., 
2012).  Plexin B1 is found in endothelial cells and SEMA 4D signalling through Plexin 
B1 induces this angiogenic effect. Studies on porcine aortic endothelial cells showed 
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this effect occurs through the binding of the Rho GEFs, PDZ-RhoGEF and leukaemia-
associated RhoGEF (LARG) to the PDZ region of plexin B1.  In human umbilical vein 
endothelial cells the signalling pathway required the activation of Met tyrosine kinase 
(Roth et al., 2009).  Both the Met and RhoGEF mechanism cause endothelial cell 
migration.   
 
Neuronal guidance: The Sema 4D- Plexin B1 signalling pathway is also involved in 
neuronal development where they act as guidance cues. For instance experiments 
carried out on mice revealed that during development GnRH-1 secreting nerve cells 
require the presence of Semaphorin4D and Plexin B1 in order to migrate to the 
hypothalamus (Giacobini et al., 2008). It was shown that the signaling pathway also 
involved the phosphorylation of Met and that Plexin B1 deficient mice showed reduced 
migration to the hypothalamus from their olfactory origin.    
 
Other Semaphorins 
Immunity: 
Other Semaphorins have been shown to be involved in the immune system (Roth et al., 
2009). Including SEMA 4A, SEMA 7D and SEMA 3A.  SEMA 4A is expressed on the 
surfaces of B cells and DC and its receptor in immune cells is Tim 2, which stands for T 
cell Ig and mucin domain 2. Tim 2 is found in activated T cells. SEMA 4A increases T 
cell activity by binding to its receptor rather than stimulating B cell activity.  SEMA 7A is 
found in activated lymphocytes and its main receptor is Plexin C1. It may play a role as 
a negative effector on T cells helping to regulate their response (Roth et al., 2009). 
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SEMA 3A and its co receptor neuropilin 1 are found in the thymus and their levels 
increase during the maturation of the thymocytes. SEMA 3A is found on the surfaces of 
activated T cells and DC. Neuropilin 1 and SEMA 3A are involved in the negative 
feedback control of T cells production as shown when antibodies against SEMA 3A in 
DC and T cell co cultures caused an increase in T cell production(Lepelletier et al., 
2006). 
 
Angiogenesis: 
There are other Semaphorins, such as SEMA 3E and SEMA 3A that are also involved 
angiogenesis.  For instance SEMA 3E, which is the only class of SEMA 3 that does not 
require neuropilins to function, is expressed in developing endothelial cells along with its 
receptor Plexin D1(Neufeld et al., 2012).  The presence SEMA 3E causes the organised 
growth of blood vessels within the boundary of the developing somite through its 
interaction with the receptor Plexin D1.  In the heart, SEMA 6D and its receptor Plexin 
A1 are involved in embryonic development (Tran et al., 2007).  This has been shown 
both in chicken and mice studies where the developing ventricular chambers were 
found to be influenced by the repulsive effect of SEMA 6D. It was found that chicken 
hearts are thinner and smaller in the absence of SEMA 6D or the receptor Plexin A1. 
 
Development: 
In lung development the Semaphorins also have an important role to play.  They are 
involved in the development of blood vessels required for gaseous exchange.  In terms 
of lung tissue specifically studies on mice lung tissue have revealed the presence of 
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SEMA 3A, 3C and 3F in invitro mouse lung tissue (Potiron et al., 2009). It appears 
SEMA 3A is located in the mesenchyme involved in inhibiting branching of the lung tree 
whereas the other two are involved in promoting growth through branching. Neuropilin 1 
and 2 are also involved, as is Plexin A1 the receptor. It appears the SEMA 3A is 
involved early on the regulation of the growth of the main branches and later on its 
expression falls.  SEMA 3C and 3F are involved in the growth of the terminal segments. 
Both the SEMA3F mRNA and protein have been shown to be expressed in adult human 
lung tissue.  
 
There are a number of semaphorins and plexins that are involved in the body’s skeletal 
development.  The first stage of bone development is the transformation of cartilage that 
originates from chondrocytes to bone. Two important bone cell types are involved, 
osteoblasts that produce new bone material and the osteoclasts that reabsorb bone 
ensuring normal bone density is maintained as their roles balance out. The Plexin A1 
and A2, SEMA 6D, SEMA 7A, SEMA 3A, and neuropilin 1 are involved in the skeletal 
development. Studies have shown the expression of SEMA 6D in osteoclasts; Plexin 
A1, A2 in chondrocytes and osteoblasts (Perala et al., 2012). In Plexin A1 knockout 
mice there is a defect in the regulation of osteoblastic function with resultant increase in 
bone and skeletal deformities.  Plexin A1 is the receptor for SEMA 6D.  Polymorphism 
of Plexin A2 is linked with osteoporosis in women and Plexin A2 may be used as marker 
for the disease (Roth et al., 2009).  SEMA 7A is expressed by osteoblasts and may be 
essential for the production of new bone. A recent mouse study involving SEMA 3A 
seems to offer hope as a plausible therapy for osteoporosis where mice with deficient 
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bone states improved following injection of SEMA 3A into their blood stream (Hayashi et 
al., 2012). It is expressed by osteoblasts, osteoclasts and chondrocytes and seems to 
be a crucial semaphorin in conjuction with neuropilin 1 in bone homeostasis (Roth et al., 
2009). It appears to be osteoprotective by increasing osteoblastic activity while reducing 
osteoclastic effects. Plexin D1 is also important when it comes to the development of 
the vertebrae with Plexin D1 knock out being fatal in mice, as they were incompatible 
with life, having split or fused vertebrae.    
 
In the kidney Semaphorins 3A and 3F and their receptors neuropilin 1 and 2 are 
expressed and have been shown to have a role in the morphogenesis of the kidney. 
SEMA 3A is important in the development of the glomerular filtration barrier through the 
negative control on the development of the podocytes. It also has an inhibitory effect on 
the branching of the ureteric bud as discovered with knockdown Plexin 3A experiments. 
There is also a negative effect on the migration of the endothelium during development 
of the kidney(Reidy and Tufro, 2011, Roth et al., 2009). The SEMA 4D-Plexin B1 
signalling pathway also seems to have an inhibitory effect on the ureteric branching by 
activating Rho A but without the influence of Met.  
 
 
Semaphorin, Plexin and Cancer 
The Semaphorins and their receptors play a role in disease processes in the human 
body. One such disease is cancer.  There are several studies that show this link with 
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cancer ranging from the involvement of semaphorins in angiogenesis to the direct link 
with invasion and metastasis of tumour cells (Tamagnone, 2012).    
 The Semaphorin family has been shown to be involved in preventing tumour 
angiogenesis and metastasis like the Semaphorin 3 group while other semaphorins 
have been shown to promote angiogenesis and metastasis like Semaphorin 4D 
(Sakurai et al., 2012). 
 
Angiogenesis is the process of new blood vessel formation and it is an essential part of 
the normal functioning of the body. Angiogenesis is also vitally important for major 
diseases like cancer both in terms of survival and progression and this has lead to the 
development of anti-angiogenic drugs for the treatment of cancer.  
There are a number of factors involved in angiogenesis, one such key factor being the 
vascular endothelial growth factor VEGF. Not only is VEGF involved in normal 
angiogenesis but also in pathological angiogenesis such as in cancer as will be 
discussed below.  Examples of other factors are platelet derived growth factor (PDGF) 
that activate smooth muscle cell growth and multiplication which is important in new 
vessel formation.  Other factors include the fibroblast growth factor (FGF), that are 
responsible for the proliferation of blood vessels, smooth muscles and fibroblasts, 
Angiopoietin-Tie family that stabilize blood vessels and EphrinB2-EphB4 pathway that 
are involved in the differentiation of larger vessels of veins and arteries (Shibuya, 2008).  
The VEGF group in humans are made up of at least four members; VEGF-A, VEGF-B, 
VEGF-C, VEGF-D.  VEGF-A is the most important of the group and contains the 
subgroup VEGF-A 121, VEGF-A165 and VEGF-A189, the differences occurring due to 
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alternative splicing(Neufeld et al., 2012).  Type 165 and 189 have the basic stretches in 
the carboxyl terminal region, while the type 121 does not. VEGF-A according to mice 
studies appears essential for embryonic survival and is involved in development for new 
blood vessels from scratch and angiogenesis (Shibuya, 2008). VEGF-A has the 
neuropilins as a receptor and this is significant in relation to the class 3 Semaphorins. It 
is only Sema 3E that combines directly with plexin-D1, and does not interact with a 
neuropilin. 
 
It was initially discovered that neuropilin 1 then neuropilin 2 are the receptors for VEGF-
A165, and this lead to the link between semaphorin 3s and angiogenesis. As the 
semaphorin 3s shared the same receptors as these VEGFs, like Sema3A that has 
neuropilin 1 as a receptor, inferences were made that they would be anti-angiogenic by 
competitively inhibiting the VEGFs through the receptor. These inferences were 
confirmed by trials (Neufeld et al., 2012, Maione et al., 2012). The Sema 3 group are 
important in tumour regulation as by being anti-angiogenic it can be inferred that they 
may play a role in diminishing the growth of tumours and potentially they may be found 
in low levels in these cancer tissues.  These inferences have been backed up by 
different studies, reviewed below, that show this link and importantly show how this 
group of semaphorins can be used as treatment of cancer especially in combination 
with other anti-angiogenic agents. 
 
Maione et al in their study highlighted the issue of the current pitfalls of anti-angiogenic 
treatment such as sunitinib, a tyrosine inhibitor(Maione et al., 2012). These drugs 
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though initially effective in treating solid tumours, causing shrinkage and hypoxia 
eventually the tumour develop resistance and continue invading and eventually 
metastasize. They hypothesize that this resistance is due to the hypoxia that the 
tumours face with anti-angiogenic treatment which leads to increased invasiveness in 
search of more blood supply. The increased invasiveness may either be due to the 
increased in heptatocyte growth factor, increasing HIF 1 alpha expression or reduced 
expression of E-cadherin. In order to test their hypothesis the study was devised with 
two different types of mouse models of cancer; cervical and neuroendocrine pancreatic 
cancer. With each one they tested the effect of sunitinib only, Sema 3A only and 
combined effect of Sema 3A and sunitinib. It was shown that Sema 3A on its own was 
more effective in preventing metastatic spread compared to sunitinib and control but the 
effect of combined therapy had the greater effect with prolonged survival and 
remarkably some of the RIP-Tag mice (the pancreatic tumour mouse model) were found 
to have no tumours. The findings were similar in the cervical tumour mouse model 
(HPV16E2), with the sunitinib actually causing more liver metastasis compared to 
control and Sema 3A only, and the combined therapy being much more effective 
causing a clear drop in the number of metastases.  
 
The effect of Sema 3A was attributed to a decrease in hypoxia within the tumour by 
normalising the vasculature as shown through pimonidazole immunostaining. There 
was also a reduced expression of HIF 1 alpha expression in the combined therapy 
group. Therefore it was proposed that this improvement in outcome was due to reduced 
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tumour hypoxia, which prevents invasiveness as well as increasing the uptake of 
chemotherapeutic agents within the tumour.  
 
The other members of the Sema 3 group have also been shown to have a detrimental 
effect on tumours as in seen in the work of Neufeld et al (Neufeld et al., 2012). This 
group worked both on glioblastoma cell lines and mouse models to show the effects of 
the Sema 3 group on this form of brain tumour that is known to be highly vascularized. 
The first step was to transfect the glioblastoma cell line U87MG with six of the Sema3 
group (A,B,D,E,F and G) excluding Sema3C. They showed differing morphological 
changes in the cell line depending on the type of Sema 3.  There was contraction of the 
cells transfected with Sema 3A and Sema 3B and Sema 3F but not with the others. 
They also had reduced rates of proliferation in anchorage free growth in agar. These 
transfected cells were then implanted subcutaneously into nude mice and it was found 
that they all, except Sema 3G, inhibited tumour formation on these mice compared to 
control. The strongest effect being with sema 3D and Sema 3E. To further verify their 
findings they injected U87MG expressing luciferase into the cortex of CD-1 immune 
deficient mice and found that again besides Sema 3G and control, there was no 
luminescence seen in the other mice with transfected Sema 3s.  Another glioblastoma 
cell line was also used, U373MG, with very similar results. This study showed greater 
effect within the brain of the Sema 3s compared to subcutaneous implantation which in 
turn had a more potent effect than the in- vitro work.  The results of this study has been 
supported by papers with the general consensus being that the Sema 3 group are have 
a negative effect on tumour progression and may be used as a form of treatment for 
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patient with cancer (Neufeld et al., 2012, Sakurai et al., 2012). The exact mechanism of 
action for this group of semaphorins, are still being clarified but seem to suggest mainly 
an anti-angiogenic effect on these cancers. 
When it comes to lung cancer so far the bulk of the evidence points again to the Sema 
3s (Potiron et al., 2009). It appears that there is a lack of or relative reduction in some 
cases of lung cancer. Both types of lung cancer, small cell carcinoma (the more 
aggressive form) and non-small cell carcinoma commonly start off with a mutation, such 
as a deletion in chromosome 3p.   This is of interest as it is the same chromosome that 
codes for Semaphorins.  Sema 3F and Sema 3B are the two most linked with lung 
cancer with a reduced expression in a certain form of non-small cell carcinoma. It was 
shown through a transfection study that Sema 3B reduces the proliferation of lung 
cancer and Sema 3B was also found to cause the death of the cells.     
There are other semaphorins that along with their receptors are known to have the 
opposite effect that is, aid the progression of cancer. However in the case of Sema 4D 
and Plexin B1 which shall be discussed later it may either promote or work against 
cancer progression depending on the interactions with its co receptors (Tamagnone, 
2012).  
 
Pancreatic cancer often presents late and has a poor prognosis, usually an average of 6 
months. A study by Sandanandam et al has revealed the link between pancreatic 
cancer and Sema 5A in partnership with its receptor plexin 3B (Sadanandam et al., 
2012). This group have shown using western blotting technique that there is an increase 
in the expression of Sema 5A protein in pancreatic cancer cell line Panc1.  It was in this 
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same line they had earlier identified the expression of plexin B3. They were also able to 
show through proliferation assays that Sema 5A is pro-angiogenic being able to induce 
endothelial cell proliferation.  They went onto inject nude mice with pancreatic cancer 
lines transfected with Sema 5A and showed that although there was a lower tumour 
load, there was an increase in micrometastases.
43 
 
Semaphorin 4D, Plexin B1 and Cancer  
Semaphorin 4D and its plexin B1 have been linked to breast cancer (Worzfeld et al., 
2012). Worzfeld et al in their recent paper showed that in ErbB2 positive breast cancer 
Plexin B1 is able to be activated without its ligand Semaphorin, in the environment of 
over expression of ErbB2. They also showed that there is a correlation with increased 
Plexin B1 expression and poor prognosis of breast cancer positive for ErbB2. In 
contrast low levels of plexin B1 are correlated with poor prognosis in ER positive breast 
cancer (Okada et al., 2015).  An increased expression of semaphorin 4D is seen in 
head and neck squamous carcinoma (Basile et al., 2006). Basile et al showed through 
tissue array studies that sema 4D expression was enhanced in prostate, breast, colon 
and lung cancer compared to normal tissue. 
 
 
Prostate cancer a review 
 
Background: 
Prostate cancer is a significant disease.  It is the most frequently occurring cancer in 
men in the UK with an incidence of 37,051 in 2008, accounting for 24% of newly 
diagnosed cancers in men. The incidence of the disease has increased steadily over 
the past 30 years and may be due in part to PSA testing and incidental findings after 
TURP operations.  On the other hand mortality from the disease has remained steady 
over the same period. In men with the disease the overall mortality is approximately 3% 
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(2012, Quinn and Babb, 2002, Kirby and Fitzpatrick, 2008). This trend is shown in graph 
1 below. 
 
Graph 1: Courtesy of Cancer Research UK(2012) 
 
 
There were 10,168 deaths from the disease in 2008, accounting for 12% of deaths in 
males due to cancer.  It is the second most common cause of deaths from cancer after 
lung cancer. It is a disease that affects older men, with ¾ of the men affected being 
aged above 65 (Crawford, 2009, 2012). The largest number of cases diagnosed is 
between the ages of 70 to 74 years. Interestingly in the UK there is a socio economic 
correlation with the disease with the incidence being higher in the more affluent (Quinn 
and Babb, 2002).  
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Aetiology; Pathophysiology; Diagnosis and Natural history of Prostate cancer: 
The aetiology of prostate cancer remains mainly idiopathic (Grover and Martin, 2002). 
There are a variety of risks factors associated with prostate cancer, the main being age 
as alluded to earlier (Crawford, 2009). Other risk factors include diet, race, obesity, 
family history and genetics. The association with diet is best shown in studies on 
migrants moving from places of low risk such as China and Japan to western countries 
(Grover and Martin, 2002). The migrant population’s risk of prostate cancer increases 
especially in second generations with the adoption of western style diet.  There is a 
strong racial association in prostate cancer. For instance in the USA between 2001 and 
2005, black men were twice as likely to be affected compared to white men with an 
incidence rate of 259 per 100,000 in black men compared to 157 per 100,000 in white 
men (Ries, 2005). In terms of genetics and family history in prostate cancer it has been 
shown that males with first degree relatives with prostate cancer have a 2.0 relative risk 
of developing the disease and a relative risk of 8.8 if he has both a first-degree and 
second degree relative with the disease(Steinberg et al., 1990).  Another important 
factor in the pathology of prostate cancer is the hormonal link. The link between 
hormones and the prostate has been documented as early as the 18th century when 
John Hunter described the effects of castration on the prostate of bulls when he 
observed castrated bulls had smaller prostate glands and reduced secretions as 
compared to their non-castrated conterparts (Marks, 2004). Although testosterone is the 
primary circulating androgen it is dihydrotestosterone (DHT) that is the primary 
intraprostatic androgen. DHT is produced by the metabolism of testosterone by the 
intracellular enzyme 5AR. Studies such as those done by Imperato-Mcginley and 
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colleagues in 2002 on individuals with congenital 5AR2 deficiency have been important 
in highlighting the role of testosterone and DHT in male sexual differentiation (Zhu and 
Imperato-McGinley, 2009, Imperato-McGinley and Zhu, 2002). These individuals have 
normal testosterone levels. They have been found not to develop BPH or prostate 
cancer, hence the hypothesis of DHT being one of the initiating factor in the 
development of prostate cancer. 
 
The majority of prostate cancer is of the adenocarcinoma variety accounting for 95% of 
cases(Humphrey, 2012, Dunn and Kazer, 2011). The other histological variations 
include transitional cell morphology originating from the lining of the prostatic urethra. 
Other varieties include neuroendocrine, small cell and basal cell varieties (Crawford, 
2009, Humphrey, 2012). The prostate is divided into 3 main zones of which 75% is the 
peripheral zone, 20% is the central zone and 5% the transitional zone. Prostate cancer 
mainly develops in the peripheral zone accounting for about 70% with another 20% 
arising from the central zone. Prostate cancer can be localised or multifocal in nature 
most being multifocal(Crawford, 2009). 
  
The disease is diagnosed by histological analysis of prostate biopsies. Although the 
disease mainly is asymptomatic, patients can present with some lower urinary 
symptoms like increased frequency of micturition that sets up as cascade of 
examinations and investigations culminating in the histological confirmation(Dunn and 
Kazer, 2011). 
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The natural history of the disease is dependent on the stage at which it is diagnosed. 
The more aggressive the disease, as measured by Gleason score, the worse the 
prognosis and vice versa. The natural history of untreated low scoring prostate cancer 
was studied and it showed that not until 15 years did the progression free survival rate 
drop substantially. The prostate cancer mortality rate increased from 15 per 1000 
person-years during the first 15 years to 44 per 1000 person-years beyond 15 years of 
follow-up (Johansson et al., 2004). 
  
 
Plexin B1, Semaphorin 4D and Prostate cancer:  
 
Semaphorins as stated before are best known for their role in the nervous tissue but 
they have also been shown to be present in other tissues involved in angiogenesis, 
control of the immune system and formation of new organs (Eickholt et al., 1999, Wong 
et al., 2007). It is this Sema4D-Plexin B1 signalling pathway that may be harnessed by 
the cancer cells during invasion and metastasis. It has been shown by Wong et al in 
2007, that in prostate cancer there is an increased expression of Plexin B1 relative to 
non-cancerous prostate tissue(Wong et al., 2007).  They found there was a significant 
difference between the levels of cores staining positive for Plexin B1 in 85 samples of 
primary prostate cancer tissue when compared to 85 samples of non-cancerous 
prostate tissue using a tissue array of radical prostatectomy samples. This significant 
increase in Plexin B1 was also replicated when quantitative reverse transcription PCR 
was performed. This study showed an increased level of expression of plexin B1 RNA in 
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cancer tissue compared to non-cancer. A high level of somatic missense mutations 
were found in prostate cancer tissue as well as metastatic lymph nodes compared to 
non-cancerous tissue.  These mutations were shown to cause altered function in the 
cells such as increased cell motility which is linked to progression of cancer. This higher 
level of expression and mutation of Plexin B1 evident in prostate tumours suggests that 
Plexin B1 has a role in prostate cancer and is a potential target for therapy(Wong et al., 
2007).  
 
MicroRNAs overview 
MicroRNAs are small RNAs that are approximately 19 to 25 nucleotides in length that 
do not code for proteins but play an important role regulating gene expression (Medina 
and Slack, 2008)They perform this regulatory function by mainly inhibiting  translation or 
causing the degradation of mRNA(Almeida et al., 2011). MicroRNAs are important in 
physiological and pathological processes in the human body as it is estimated that up to 
60% of all coding RNA are regulated by microRNAs(Friedman et al., 2009). This means 
that they directly affect the majority of cellular activities, one microRNA has many 
mRNA targets. MicroRNAs are highly conserved across species with humans having 
the highest number and according to the latest version of mirbase, the microRNA 
database, there are 2,588 mature human microRNAs(Mirbase).  
 
Discovery and history of microRNAs  
The study of microRNAs is still relatively recent as their existence was first reported in 
1993 by Lee et al, when researching the lin-4 gene in the C Elegans (Lee et al., 1993). 
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It was found that lin-4 was essential for the sequential development of the larval stage 
of C Elegans as mutations that caused loss of function of the lin 4 gene led to 
developmental abnormalities. The abnormalities included the retention of features 
typical of early stages in the adult animal including extra larval molts, abnormal cuticles 
and the inability to lay eggs. It was the discovery of the link between lin 4 and another 
gene lin 14 in the C Elegans, that led to what we now know as microRNAs.  C Elegans 
with an increased expression of lin 14 due to a mutation of the lin 14 gene region were 
found to have the same effect as the loss of function lin 4 mutation. This lead to the 
investigation of the lin 4 gene as a negative regulator of the lin 14 gene. Firstly lin 4 was 
found not to code for any protein.  It was also found to encode for two mRNA transcripts 
one of which was 22 nucleotides in length.  On further investigation part of the 
sequence of these small RNA was complimentary to the 3’UTR section of the lin 14 
RNA. They showed that this 3’UTR section of mRNA was mutated in the C Elegans with 
lin 14 gain of function mutation, proving that the negative regulation of lin 14 by lin 4 is 
through the 3’UTR end of lin 14 (Lee et al., 1993). It was this discovery that has led to 
the microRNA era and we now understand that microRNAs are small non coding RNAs 
that function mainly by binding to the 3’UTR end of their target mRNA and thereby 
regulating their expression. The mechanism of action may also include binding to the 
coding region and the 5’UTR ends (Pang et al., 2010).  
 
Biogenesis of MicroRNAs 
 MicroRNAs start off by being transcribed in the nucleus and are then transported to the 
cytoplasm where they mature to effect change on mRNAs. MicroRNAs are initially 
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transcribed by the enzyme RNA polymerase II, into the primary microRNA transcripts 
termed pri-miRNA. There are also a smaller number of microRNAs that are transcribed 
by RNA polymerase III (Etheridge et al., 2011). The pri-miRNAs are double stranded 
long structures with stem loops comprising of tens to hundreds of nucleotides (Kim et 
al., 2009, Casanova-Salas et al., 2012). These pri-miRNAs do eventually produce 
multiple mature miRNAs. Pri-miRNAs are broken down within the nucleus into precursor 
microRNAs (pre-miRNAs) by a protein complex called the Microprocessor. This 
microprocessor has two main components; Drosha an RNA polymerase III, and the co 
factor called DiGeorge syndrome critical region 8 (DRCG8) a double stranded RNA 
binding protein.  The microprocessor complex breaks down the pri-miRNA at the stem 
region of the stem loop, into 60 to 110 nucleotide pre-miRNAs that resemble hair-pin 
like structures. The pre-miRNA are then exported from the nucleus into the cytoplasm 
through the nuclear pore by Exportin-5, a double stranded RNA binding nuclear 
transport receptor, that also transports transfer RNA (Winter and Diederichs, 2011) . 
Exportin-5 transports the pre-miRNA by combining with RAN-GTP, and on the 
hydrolysis of the GTP in the cytoplasm the pre-miRNA is unbound(Ha and Kim, 2014). 
Once in the cytoplasm the pre-miRNA is broken down further into mature miRNA by the 
RNA polymerase III called Dicer. The Dicer does this by cleaving off the loop section of 
the pre-miRNA leaving a duplex miRNA. One of the two strands becomes the mature 
miRNA, the other, the complementary sequence of the duplex, is eventually degraded.  
The mature miRNA combines with the Argornaute protein to form the RISC (RNA 
induced silencing complex)(Lujambio and Lowe, 2012, Russo and Giordano, 2009). The 
RISC gives the miRNA stability with which it interacts with mRNAs 
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through it’s “seed’’ region, which is a 6-8 nucleotides region at the start of the 5’ end of 
the miRNA (Ameres and Zamore, 2013) . The figure 11 below is a schematic 
representation of miRNA biogenesis. In the biogenesis process sometimes both strands 
become active miRNAs because none get degraded(Ha and Kim, 2014). One of the 
strands is named 5p as it originates from the 5’ strand of the pre-miRNA, while the 
complementary sequence is termed 3p originating from the 3’ strand, an example being 
mir532-3p(Ha and Kim, 2014).  
Figure 11: A Schematic diagram of miRNA biogenesis 
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The physiological role of microRNAs 
The physiological role of microRNAs is to regulate RNA expression and therefore 
ultimately gene function. The regulatory role of microRNAs on mRNA is due to 
complementary binding of base pairs. The 6-8 nucleotide “seed” region of the 
microRNA, at the start its the 5’UTR end complements the 3’ region of a particular 
mRNA and the level of pairing leads to the complete degradation of the mRNA or a halt 
to its translation(Shukla et al., 2011).  This occurs mainly within the confines of the cell 
wall. 
 
Although microRNAs are produced within the cell they have been shown to exist in 
varying quantities in different extracellular compartments (Weber et al., 2010). It 
appears they are ubiquitous as the study by Wang et al showed that microRNAs exist in 
all the 12 different body fluids they tested from serum to saliva (Wang et al., 2010). 
MicroRNAs, unlike other RNAs, are stable within the extracellular environment and even 
within fixed formalin tissue. This has been suggested to occur because they are found 
to be either within protective secretive vesicles and exosomes or bound to proteins such 
as nucleophosmin 1 (NPM1) or the Argonaut 2 complex, part of the RISC 
complex(Wang et al., 2010, Selth et al., 2012, Etheridge et al., 2011). Wang et al, for 
example, showed in their study that miRNAs such as mir-122 were bound to the NPM1 
protein and that this protein provided protection against ribonuclease activity in the 
extracellular environment(Wang et al., 2010). Others have shown that miRNAs are able 
to exist for a substantial amount of time without decay in serum and even so after 
subjecting them to repeated freeze-thaw cycles (Chen et al., 2008). 
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Due to their existence in the extracellular compartment, there is a debate about the 
function of microRNAs within this area of the body. It is thought that they may exist in 
circulation due to the lysis of dead cells or perhaps they are actually a means of cell to 
cell communication (Wang et al., 2010, Selth et al., 2012). It has been suggested that 
microRNAs may be released specifically into the circulation depending on the bodies 
requirements and just like hormones set off a cascade of events by communicating to 
distant sites within the body(Kelly et al., 2013).   
 
 
 
 
MiRNA and cancer 
The possibility that microRNAs could be linked to cancer was first highlighted by the 
work of Calin et al (Calin et al., 2002). There is a common deletion in chromosome 
13q14.3 found in patients with chronic lymphocytic leukaemia (CLL). The group 
investigated the genes found within the deleted region of the chromosome 13q14.3 to 
discover if any of them could be linked to the CLL. They identified two particular genes 
in the deleted region that coded for microRNAs 15 and 16 as the most likely candidates 
linked to CLL. The deletion at chromosome 13 has also been associated with other 
forms of cancer such as prostate cancer and multiple myeloma. On further investigation 
they also found a reduced expression of these microRNAs. They showed in their study 
that levels of microRNA 16 and MicroRNA 15 were reduced in at least 60% of patients 
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with CLL. The exact role of these microRNAs in leukaemia is still being investigated. It 
appears that microRNA are a significant factor in carcinogenesis as this group showed 
they often reside in weak areas of chromosomes (fragile sites), or missing sections of 
chromosomes liable to predispose to cancer(Calin et al., 2004). A possible mechanism 
of action in CLL was highlighted by a subsequent study by the group (Cimmino et al., 
2005). They showed that the reduced expression of both microRNAs 15 and 16 in CLL 
are linked to the increased expression of B cell lymphoma 2(BLC2) protein, the protein 
linked to preventing apoptosis in B cell lymphoma. They studied the nucleotide 
sequences, and noted the 3’UTR end of the BLC2 mRNA is complementary to the first 
nine nucleotides of the 5’ end of both microRNAs 15 and 16. Therefore they suggest the 
low levels of the microRNAs that occur in cases of CLL described earlier allowed for the 
increased expression of BLC2 protein and thus the link to CLL pathology (Cimmino et 
al., 2005). Trials of a drug ABT-199 that selectively blocks BCL2 protein have shown 
promising results in both animal models and an initial trial with patients with CLL, thus 
further suggesting the link between miRNAs 15 and 16 and CLL(Souers et al., 2013). 
 
There have now been a number of studies linking miRNAs to various forms of cancer 
either as oncogenes or tumour suppressors.  Other studies have investigated the 
important roles the RNA polymerase III enzymes drosha and dicer, key factors in the 
biogenesis of miRNA, may play in carcinogenesis(Lujambio and Lowe, 2012).  
 
The prevailing consensus is that the miRNA biogenesis factors drosha and dicer have 
roles as tumour suppressors(Merritt et al., 2008, Khoshnaw et al., 2012, Zhu et al., 
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2012). Karube et al looked into the influence dicer and drosha had on non-small cell 
lung cancer patients to investigate any relationship to the prognosis of the 
disease(Karube et al., 2005). Their hypothesis was linked to previous findings of low 
levels of the miRNA let 7 in non-small cell lung cancer (NSCLC), and they indeed found 
significant low levels of dicer was linked to poor prognosis in these patients(Karube et 
al., 2005). The investigation involved analyzing the samples of patients that underwent 
potentially curative surgery and following up their survival, using the quantitative real 
time polymerase chain reaction qPCR to quantify dicer levels. Other studies have found 
similar results in different cancers such as ovarian in the case of Merritt et al (Merritt et 
al., 2008), and also in breast cancer (Khoshnaw et al., 2012). These studies have not 
only looked into the levels of the RNA through qPCR, as in the case of Karube et al, but 
also compared the protein levels in tissue samples as well as standardized their results 
by comparing to normal tissue samples(Merritt et al., 2008). However more recent 
studies appear to suggest relationship to cancer is not as straightforward as shown in 
initial studies. For instance the link with prognosis and dicer levels in NSCLC appears to 
be only in certain sub groups and not in all patients when it was studied recently by 
Lonvik et al(Lonvik et al., 2014). Other groups have shown that in some other cancers 
low levels of dicer are linked with better prognosis as in the case of colorectal 
cancer(Vincenzi et al., 2013). The exact relationship is likely to be complex as shown in 
a recent study by Adams et al (Adams and Eischen, 2014), and may depend on cancer 
type, but there appears to be potential in this area for cancer therapeutics and future 
studies will no doubt shed more light on this. 
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With respect to miRNAs acting as oncogenes, there are a number of miRNAs that have 
been identified with this property such as the microRNAs  mir 21 and mir 155(Si et al., 
2007, Medina et al., 2010, Costinean et al., 2006).  Mir 21 for instance has been shown 
to be upregulated in a variety of cancers such as breast cancer as shown by Si et al(Si 
et al., 2007).  Their study compared the levels of mir21 in breast cancer tissue with 
matched normal samples using qPCR on an miRNA array and found the levels of mir21 
to be elevated in the cancer tissue. They also showed that breast cancer cells 
transfected with anti-mir21 had a dose dependent decrease in growth and confirmed 
this in mouse models (Si et al., 2007). A further study this time on mice engineered to 
express mir21, showed that an increased mir21 expression caused lymphoma like 
effects on the mice in those mice that had the mir21 expression switched on which 
remarkably regressed once the mir21 was blocked to further suggest mir21 role as an 
oncogene(Medina et al., 2010). Another study looked at the involvement of mir21 in 
prostate cancer and found it was overexpressed in the disease and particularly linked 
with recurrent prostate cancer(Leite et al., 2015). Mir 155 is another miRNA that has 
also been shown to act as an oncogene. This was exemplified by Costinean et al 
(Costinean et al., 2006)when the transgenic mice they created to overexpress mir155 
showed acute lymphoblastic lymphoma like disease suggesting a role of mir 155 in the 
initiation or progression of the disease.  
MiRNAs have been shown to have tumour suppressor capabilities for instance as 
mentioned earlier in the first paragraph of this section in the case of the mir15 and 
mir16.  
 
57 
 
The mir34 family is another example that has been studied extensively for its tumour 
suppressive properties(Lodygin et al., 2008, Kasinski et al., 2014, Asmar et al., 2014). 
This family of miRNA is important and is part of the p53 tumour suppressor cascade, as 
shown by He et al(He et al., 2007). Their study found p53 controls the transcription of 
the mir 34 family. A study by Asmer et al on B cell lymphoma patients showed that in 
certain subgroups a combined defect in p53 and mir34a had a more negative prognostic 
effect than defects in p53 alone(Asmar et al., 2014). Thus suggesting mir34 has an 
important tumour suppressive role in its own right. Lodygin et al found the levels of mir 
34a were reduced in a variety of cancer cells such as breast, prostate, bladder and 
melanoma (Lodygin et al., 2008). It is also reduced in B-cell lymphoma and it appears to 
follow a progressive pattern, significantly lower in high grade compared to low-grade B-
cell lymphoma (Craig et al., 2011). These findings have led to studies into the potential 
therapeutic use of mir34 in cancer. For instance in a recent study by Kasinski et al, 
mir34a was transfected into non-small cell lung cancer cell lines and also injected into 
mouse models of the disease(Kasinski et al., 2014).  The study found that the animals 
injected with the lipid based nanoparticle containing the mir34a had a reduction in 
tumour size compared to the control. To ascertain the clinical utility of this technique a 
phase one study is currently in progress using this nanoparticle in human subjects with 
liver metastases(Bouchie, 2013).  Among other tumour suppressor miRNAs, we also 
have let 7 miRNA, as also shown in the Kasinski et al study where their effects were 
similar to mir34a on the cell and animal models of lung cancer(Kasinski et al., 2014). An 
interesting study by Trang and colleagues showed the gradual reduction in the levels of 
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let 7 as the lung tumour became more aggressive(Trang et al., 2010). This inverse 
relationship further strengthens the suggestion that let 7 is a tumour suppressor.   
 
Another important tumour suppressor miRNA is mir1. This miRNA has been shown by 
several studies to act as a tumour suppressor in several cancers such as prostate, lung, 
mesothelioma and bladder (Letelier et al., 2014, Mataki et al., 2015, Xu et al., 2013, 
Hudson et al., 2012, Yoshino et al., 2012). In the study by Letelier et al, using 
microarray analysis of bladder cancer tissue and validating their data by qRT-PCR, mir 
1 was shown to have significantly reduced expression compared to normal 
tissue(Letelier et al., 2014). Mir 1 was also shown to induce apoptosis and reduce cell 
growth when transfected into the bladder cancer cell line NOZ(Letelier et al., 2014). In 
terms of discovering the mechanism of action of mir 1 in bladder cancer they highlighted 
the protein VEGF-A, a protein that is essential in many instances for angiogenesis and 
found in high levels in bladder tumour with poor prognosis(Letelier et al., 2014). VEGF-
A was repressed by mir1 in this study by Letelier. They suggest the reduced level of mir 
1 in bladder tumour is a possible cause for the level and effect of VEGF-A in this 
tumour(Letelier et al., 2014). Other studies such as that by Mataki et al(Mataki et al., 
2015), have also shown significant reduction in cancer characteristics such as 
proliferation, migration upon transfection of mir1 this time into lung cancer cell lines.  
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MiRNA and prostate cancer 
In the case of prostate cancer, studies have not only shown a link between mir1 and the 
disease but also suggested that it is linked to prognosis of the disease as exemplified by 
further down regulation of mir1 levels in metastatic disease and by mir 1 being 
independently associated with the recurrence of prostate cancer(Hudson et al., 2012). 
The study by Hudson et al in 2012 showed that the effect was due to repression of 
targets such as BRCA1 and that mir 1 also inhibited invasion and filopodia formation in 
the prostate cancer cell line LNCaP(Hudson et al., 2012). Interestingly this study 
showed that the complementary sequence of BRCA1 to which the seed region of mir1 
binds to was found among the coding sequence of BRCA1 and not in its 3’UTR.  
 
Various studies have been done and others are ongoing to elucidate the relationship 
between miRNAs and prostate cancer. This as stated earlier is due the unique 
properties of miRNAs such as their ability to withstand degradation by ribonuclease or 
to remain intact in plasma despite repeated freeze-thaw cycles. This makes them ideal 
candidates as biomarkers for both the diagnosis and prognosis of the 
disease(Cannistraci et al., 2014).  A few candidate miRNAs have been suggested as 
diagnostic markers for prostate cancer, one such is the tumour suppressor let 7 that is 
down regulated in prostate cancer(Wagner et al., 2014). A study by Nadiminty et al in 
2012 investigated let 7c, a member of the let 7 family, looking at its link to prostate 
cancer(Nadiminty et al., 2012). They found through their work on LNCaP cell lines and 
nude mice xenografted with human prostate cancer tumours that let 7c is a negative 
regulator of the androgen receptor (AR). Let 7c negatively regulates AR which is the key 
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factor in normal prostate development and also prostate cancer through direct inhibition 
of c-Myc. C-Myc contains complimentary sequence in its 3’UTR to the seed region of 
Let 7c(Nadiminty et al., 2012). Nadiminty et al also showed in their work that Let 7c 
reduced the proliferative characteristics in prostate cancer cells.  
 
In terms of a marker for disease prognosis, among the many miRNAs that have been 
linked with prostate cancer, mir 221 has been shown in several studies to be down 
regulated in metastatic disease(Cannistraci et al., 2014, Goto et al., 2015).  One such 
study by Kneitz et al(Kneitz et al., 2014) has shown that mir221 is decreased in 
metastatic prostate cancer and correlates with treatment failure of the disease as well 
as prostate cancer related death in this advanced prostate cancer group. To verify the 
prognostic value of mir221 they studied a cohort of patients that had high risk disease, 
these patients were followed up and the outcome correlated with the levels of mir221. 
They also transfected the prostate cancer cell lines DU145,PC3 and LNCaP with mir221 
and found a decrease in growth and invasiveness in these cell lines. The clinical utility 
of mir221 is especially relevant in differentiating high risk prostate disease from low risk 
disease(Kneitz et al., 2014).  Mir154 and mir379 are among others that have been 
linked with the prognosis of the disease for instance in metastatic bone disease as 
shown by Gururajan et al(Gururajan et al., 2014). 
 
In summary this is an evolving area of study that may help in the clarification of prostate 
cancer diagnosis, prognosis and ultimately treatment of prostate cancer. 
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HYPOTHESIS, AIMS, AND OBJECTIVES 
It has been shown that plexin B1 levels are increased in prostate cancer and results 
suggest a link with prostate cancer metastasis(Wong et al., 2007). It is also known that 
the expression levels of genes and thus their effect are regulated by microRNAs. There 
have been numerous studies that have shown the link between microRNAs and cancer, 
so it is possible that the expression levels of plexin B1 in prostate cancer may be as a 
result of abberent regulation by microRNAs. A recent study by Qiang et al has 
suggested that a certain microRNA, miR 214 directly binds to the 3’UTR of plexin B1 
and so suppresses the invasive and migratory effects of plexin B1 on cervical cancer 
cells(Qiang et al., 2011).  
 
I therefore hypothesized that the elevation in plexin B1 in prostate cancer was as a 
result of one of the following two scenarios involving microRNAs; 
1. The lack of microRNA binding sites in the sequence of plexin B1 as occurs in 
alternatively spliced variants of plexin B1. 
2. The reduction in levels of certain miRNAs that normally act as tumour 
suppressors, i.e normally down-regulate the expression of plexin B1. 
 
The aim of this research project was to identify the putative alternatively spliced variants 
of plexin B1 that lack microRNA binding sites that may account for the altered 
expression levels of plexin B1. I also aimed to discover which miRNAs may affect the 
expression of wild type plexin B1 
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My objectives included: (a) characterising the plexin B1 variants. (b) Identifying the 
microRNAs that may down regulate the expression of plexin B1 (c) Confirming the 
downward regulation of plexin B1 by the identified microRNAs i.e. reduced expression 
of plexin B1 by these microRNA, both in the plexin B1 mRNA and protein levels.
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Chapter 2 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
Cell lines 
The first step in this project was to confirm the existence of Plexin B1 mRNA in the 
chosen 9 cell lines. The 9 cell lines were as follows; PC3, DU145, LNCaP, 1542CP, 
1542NP, YUSIK, GCT27, T24 and 22RV1. PC3 was first isolated by Kaighn et al from a 
lumbar vertebrae bony metastasis of a patient with prostate cancer(Kaighn et al., 1979). 
DU145 are epithelial cells derived from a tumour mass excised from the brain of a 69 
year old man with prostate cancer and lymphocytic leukaemia(Stone et al., 1978). 
LNCaP was derived from a lymph node metastasis of a patient with prostate 
cancer(Horoszewicz et al., 1980). 1542 NP and 1542CP were derived from resected 
benign and malignant prostate tissue respectively from a patient with prostate 
cancer(Bright et al., 1997). 22RV1 are primary prostate carcinoma cells with bony 
metastasis derived from xenografts(Sramkoski et al., 1999). YUSIK is a cell line derived 
from lymph node metastasis of melanoma patient(Aziz et al., 2010). GCT27 is derived 
from a human germ cell testicular tumour cell line(Pera et al., 1987). T24 cell line is 
derived from a primary transitional cell carcinoma of the bladder(Bubenik et al., 1973). 
 
YUSIK (melanoma) was used because PlexinB1 is thought to act as a tumour 
suppressor gene in melanoma. Prostate cancer cell lines (PC3, DU145, 1542C, 22RV1, 
LNCaP) and normal prostate cell line (1542NP) were used to determine if the potential 
Plexin B1 variants identified were cancer specific.  I used the GCT27 (testicular germ 
cell) cell line and T24 (bladder) cell lines to determine if the potential Plexin B1 variants 
identified were also expressed in other urological cancer cell lines.  
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Cell culture 
All cell lines were cultured in RPMI 1640 media (Invitrogen) supplemented with L-
glutamine 5% and 8% foetal bovine serum. All cell lines were grown in T25 flasks at 
37°C, in 5% CO2 and passaged at 80-90% confluency. 
Each passage was made by first aspirating the medium, and the cells then washed with 
PBS.  The PBS was aspirated out of the T25 flask, and then 0.5mls of trypsin solution 
was added for a period of 5 minutes to detach the cells from the base of the flask. To 
make a passage of 1:10 ratio, a volume of 9.5mls of RPMI solution was then added to 
the T25 flask making a total volume of 10mls. Finally I made up 3 new T25 flasks by 
adding 1 ml from the cell suspension and 4mls of fresh RPMI solution to each flask.   
 
 
RNA extraction 
RNA was extracted using the Qiagen RNeasy mini kit following the Qiagen RNeasy Mini 
Handbook protocol. Once the cells were ~80-90% confluent they were washed with 
PBS, a physiological buffer, to remove serum to enhance the extraction process. The 
PBS was then aspirated and 0.1- 0.25% trypsin in PBS added to the flask. After the 
cells detached from the base of the flask, 8mls of medium was added and the content 
transferred to a polypropylene centrifuge tube and centrifuged at 300 x g for 5 min. 
The supernatant was completely aspirated and the cell pellet loosened thoroughly by 
flicking the tube. The cells were disrupted by adding the appropriate volume (600 µl, for 
5 x 106 pelleted cells) of buffer RLT (a buffer from QIAGEN used in cell lysis) and mixed 
using a pipette. The lysate was then homogenized. This was done by pipetting the 
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lysate directly into the QIA shredder spin column placed in a 2ml collection tube, and 
centrifuging it for 2 minutes at full speed. An equal volume of 70% ethanol was added to 
the homogenized lysate, and mixed well using pipetting. 700 µl of the sample was 
transferred, including any precipitate that may have formed, to an RNeasy spin column 
placed in a 2 ml collection tube. This was centrifuged for 15 seconds at ≤ 8000 x g (≤ 
10,000 rpm) and the flow- through discarded. 700 µl of Buffer RW1 was then added to 
the RNeasy spin column and centrifuged for 15s at ≤8000 x g (≤ 10,000 rpm) to wash 
the spin column membrane and the flow- through was discarded. 500 µl of Buffer RPE 
was used to wash the spin column membrane twice, firstly centrifuged for 15s at ≤ 8000 
x g (≤10,000 rpm) then centrifuged for 2s at ≤ 8000 x g (≤10,000 rpm). To dispose of all 
possible Buffer RPE the RNeasy spin column was placed in a new 2ml collection tube, 
and centrifuge at full speed for 1 min. The RNA in the RNeasy spin column was then 
eluted using 30-50 µl RNase free water added directly to the spin column membrane 
and centrifuged for 1 min at ≤ 8000 x g (≤ 10,000 rpm). The RNA is stored at -80°C. 
 
 
Experiments to identify splice variants in prostate cancer cells  
In order to identify the splice variants of Plexin B1 mRNA, an online search was made of 
the following sites; National Center for Biotechnology Information (NCBI) Reference 
sequence database, the alternative splicing in human structural genomics project at the 
website http://www.as3d.org, and the Ensembl database[6-8]. The common variants 
attributed to Plexin B1 were found as follows; 
 Variant 1: NM_002673 
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Variant 2: NM001130082.1 
Variant R: AJ011515 
Truncated variant: AJ011414 
 
To identify the above variants bespoke primers were designed by aligning the full length 
variant NM_002673 to the other variants R and truncated variant. Sense and Antisense 
primers were chosen in areas where variants R and the truncated variant had missing 
bases (at exon 11) in comparison to variants 1 and 2 (fig 1). Multiple areas of same 
bases were avoided, as were regions that could produce secondary structures e.g.- 
GGGCCCC. These primers were confirmed to be specific for PlexinB1 using the ‘blast’ 
nucleotide programme on the National Centre for Biotechnology Information at the 
website http://www.ncbi.nlm.nih.gov [7]. The 3’RACE PCR was used to identify both 
Variant R and truncated variant by amplifying their 3’ends. 
The following primers were used; 
Primer                                       Sequence (5’-3’) 
Plexin B 1 415 1 S                   CATCAACAAGTACTATGACCAG  (gene specific primer) 
Plexin B 1 415 2 S                   TGCAGCTGGGCTATCGGCTC  (gene specific primer) 
Plexin B 1 414 1 S                  TGCCTGAGTTCACGGTGCAG  (gene specific primer) 
Plexin B 1 414 2 S                  GTGCAGTATGACGGCGAGAG (gene specific primer) 
 
 
 
 
68 
 
 
Amplification of cDNA ends using 3’RACE ( Rapid Amplification of cDNA Ends) system 
The above primers are used to perform 3’RACE (rapid amplification of cDNA ends) 
PCR using a oligo dT tagged primer and a gene specific primer complementary to a 
sequence close to the stop codon.  
 
The 3’RACE system is a method of producing multiple copies of a defined area within a 
3’ (untranslated region) UTR end of a given cDNA. I followed the Invitrogen 3’RACE 
protocol using the bespoke primers for the 3’UTR of plexin B1 I made earlier. The first 
stage is to synthesize the cDNA. I first mixed and centrifuged the components then 
added 1µg of RNA extracted from the cell lines to DEPC treated water to make a final 
volume of 11µl in a microcentrifuge tube. I then added 1µl of 10µM AP solution, mixed 
gently and briefly centrifuged the reaction. The mixture was then heated to 70°C for 10 
minutes and chilled on ice for at least 1 minute. The content of the tube were collected 
by centrifugation and I then added the following; 2 µl of 10X PCR buffer, 2 µl of 25mM 
MgCl2, 1µl 10mM dNTPmix, and 2 µl of 0.1 DTT. The content in the tube was then 
mixed and centrifuged briefly equilibrating the mixture to 42°C for 5 minutes. I then 
added 1 µl of SuperScript™ II RT and Incubated the tube at 42°C in a heat block for 50 
minutes. The reaction was terminated by incubating it at 70°C for 15 minutes. I then 
chilled the tube on ice and collected the reaction by brief centrifugation. I added 1 µl of 
RNase H to the tube, mixed it, and incubated for 20 min at 37°C.  
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Then I followed the second stage of the protocol which is to amplifiy the target cDNA. I 
added the following to a fresh 0.5ml microcentrifuge tube; 5 µl of 10X PCR buffer, 3 µl 
of 25mM MgCl2 , 36.5 µl of distilled water, 1 µl of the primer, 1 µl of 10 µM AUAP, 0.5 µl 
of Taq DNA polymerase. I added 2 µl from the cDNA synthesis reaction to the tube. I 
then mixed gently and collected the reactiopn by brief centrifugation. I then incubated 
the reaction at 94°C for 3 min. I then carried out 20 to 35 cycles of PCR, according to 
the TaqDNA polymerase protocol. The sample was analysed with agarose gel 
electrophoresis and after extraction was sent for cDNA sequencing. 
  
Exon 11 experiments 
In the plexin B1 variant experiments I also used primers for exon 11 to differentiate 
Variant 1 and 2 (they have all their exon’s present in the mRNA) from variants R and the 
truncated variant (both have missing exons 11). The primers are as below; 
 
Plexin B1 Exon 11splice S    TATGACTGTGTGGCGGTCAC  (exon specific primer) 
Plexin B1 Exon 11 splice AS  CTGGTAGTCGAGGCTGGACG (exon specific primer) 
 
 
 
  
RT-PCR 
For the reverse transcriptase polymerase chain reaction (RT-PCR), RNase free 
eppendorfs tubes and tips were used for the procedure. I followed the Invitrogen 
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superscript III first strand synthesis system for RT-PCR protocol. The RNA extract was 
added to oligo dT primer, dNTP mix and DEPC- treated water to make 10 µl of mixture. 
This mixture was incubated for 5minutes at 65°C and then placed in ice for at least one 
minute. A cDNA synthesis mixture was created using the following; 2µl of 10x RT buffer, 
4 µl of 25mM Mgcl2, 2µl 0.1 M DTT, 1µl of RNase OUT and 1µl of Superscript III RT. 
This cDNA synthesis mix was added to the RNA mix and after brief centrifugation the 
resultant mixture was incubated at 50°C for 50 minutes and the reaction was terminated 
at 85°C for 5minutes and then placed in ice. The reaction was then briefly centrifuged 
and 1µl of RNase H added to each tube and incubated for 20 minutes at 37°C. The 
cDNA synthesis reaction was stored at -20°C or used directly for the PCR reaction.  
 
Two sets of mega PCR mixes were made, one with the particular plexin primers being 
investigated and the other mega mix with GAPDH primers with the following reagents 
10x buffer, Mgcl2, dNTP, primer sense and antisense, Taq polymerase and completed 
with sterilized distilled water. 
The reaction was as follows; 
The first stage was heating the cDNA product to 95°C for 3 minutes.  The second stage 
was 38 cycles of the following steps for plexin primers: A period of 1 minute of heating 
to 95°C to denature, 60°C for 1 minute to anneal, 72°C for 1 minute to elongate and 
finally the third stage is 1 cycle of heating the product to 72°C for 10 minutes.  The 
same PCR process was done for GAPDH primer except in the second stage when it 
was 30 cycles as opposed to 38 cycles.     
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Agarose gel for electrophoresis  
The cDNA PCR reaction products were analysed using a 1% agarose electrophoresis 
gel. This gel was made by first dissolving 2grams of agarose powder into 200mls of 1x 
TAE (Tris-base, acetic acid and EDTA) buffer. For the splice variant experiments to 
enhance the visualization of the individual bands of the cDNA product 3% agarose was 
used involving 6g in 200mls of 1x TAE buffer. The solution is heated up to boiling point 
to allow adequate dissolving of the agarose and once adequately cooled before it sets, 
14µl of ethidium bromide which binds to DNA was added to the mixture to aid detection 
of DNA. The agarose gel is poured into a gel cast to set and then it is placed in an 
electrophoresis tank with 1x TAE buffer solution. 
 
 
DNA gel extraction  
To extract DNA from the agarose gel, I followed the QIAquick gel extraction kit protocol 
using a microcentrifuge.  Firstly I excised the DNA from the agarose gel, weighed the 
gel slice in a colourless tube and added 3 volumes of buffer QG for 1 volume of gel 
(100mg=100µl). I then incubated for 10 minutes at 50°C when the gel dissolved 
completely, checking that the colour of the mixture was yellow similar to the QG buffer. I 
then placed the sample in the QIAquick spin column and put the column into a 2ml 
collection tube and centrifuged for 1 minute at 10,000 X g to bind the DNA. I then 
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discarded the flow through and then added another 0.5ml of buffer QG to the QIAquick 
column and centrifuged for 1 minute and discard the flow through. Then to wash the 
product I added 0.75mls of PE buffer to the QIAquick column and centrifuged for 
another 1 minute. After discarding the flow through I centrifuged for another 1 minute. 
The QIAquick column was then placed into a clear 1.5ml microcentrifuge tube and to 
elute the DNA I added 50µl of EB buffer to the centre of the QIAquick membrane and 
centrifuged the column for 1 minute at maximum speed. 
 
 
 
Cloning of the pmir GLO Vector 
The objective for this set of procedures was to make plasmid vector construct 
containing plexin B1 3’UTR that would be transfected into selected cell lines. The 
plasmid vector construct was made by the combination (ligation) of the plexin B1 3’UTR 
onto the pmirGLO vector. The pmirGLO vector contains the luciferase gene.  I first 
performed PCR of the 3’UTR end of plexin B1 using primers designed to tag the ends of 
the PCR product to enable ligation with the cut vector end. I then performed gel 
electrophoresis to confirm the existence of the product and extracted the cDNA 
following the QIAquick gel extraction kit protocol using a microcentrifuge. The pmirGLO 
vector was digested, i.e. cut and linearized, using restriction enzymes to create 
compatible ends for cloning. I then performed ligation of the cut vector and the plexin B1 
3’UTR to form a vector containing the 3’UTR of plexin B1down stream of the luciferase 
gene (Luc-3’UTR).  This ligation reaction was performed following the ligation protocol 
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with T4 DNA ligase from New England Biolabs. The reaction mixture, composed of the 
vector, the plexin B1 3’UTR, nuclease free water and T4 DNA ligase was mixed, 
incubated at 16°C overnight to ligate the sticky ends generated by the restriction 
enzyme digestion, heat inactivated at 65°C for 10 min and then chilled on ice. I then 
proceeded to transform the ligated pmirGLO vector- construct (Luc-3’UTR) into E. coli 
bacteria and selected them out on ampicillin-containing agar plates. The agar plates 
were made by autoclaving 500ml agar solution (made by dissolving 18.5g of agar into 
soomls of dionized water) and on cooling adding 500ml of 10mg/ml of filtered sterilized 
ampicillin, this resultant mixture was poured into petri dish making the agar plate. The 
transformation was performed using the NEB 5 alpha competent E. coli high efficiency 
transformation protocol, from New England Biolabs. The resultant transformed colony of 
bacteria was greatly multiplied by picking each colony using a sterile pipette tip from the 
agar plate and adding it to a mixture of sterilized ampicillin and LB solution and then 
incubating the mixture at 37°C in an incubator shaker. The Luc-3’UTR vector was 
extracted by following the QIAprep miniprep kit protocol. I then performed PCR of Luc-
3’UTR to amplify the product and then analysed the nucleotide sequence, to check the 
3’UTR end was correctly inserted into the vector. With this confirmation I proceeded to 
make more LUC-3’UTR by transforming them into more E. coli and then this time 
purifying them using Qiagen maxiprep purification protocol.  
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Transformation of pmirGLO vector-construct into competent E. coli  
The transformation was performed using the NEB 5 alpha competent E. coli high 
efficiency transformation protocol, from New England Biolabs. This involved thawing a 
tube of the NEB 5 alpha competent E. coli cells on ice for 10 minutes. Then mixing 
gently and carefully pipetting 50µl of cells into a transformation tube on ice. I then added 
1µl of the Luc-3’UTR (vector construct) to the cell mixture and carefully flicked the tube 
to mix the cell and the DNA. I then placed the mixture on ice for 30 minutes. The 
mixture was then heat shocked at exactly 42°C for exactly 30 seconds and then placed 
on ice for 5 minutes and then added 950µl of SOC using a pipette. The mixture was 
then placed in an incubator shaker and shaken vigorously at 37°C for 60 minutes.  I 
then mixed the cells thoroughly by flicking the tube and inverting, then performed 
several 10-foId serial dilutions in SOC and spread 50-100µl of each dilution onto a 
selection plate (ampicillin agar plate) and incubated overnight at 37°C. 
 
pmirGLO vector-construct purification  
The Luc-3’UTR vector was purified by following the QIAprep Miniprep kit protocol and 
also then on confirmation of the sequence more were produced using the E.coli bacteria 
transformation and then purified using the Qiagen maxiprep purification protocol.  
 
For the first purification process using the QIAprep Miniprep kit protocol I centrifuged 
5ml bacterial overnight culture at 6800 x g for 3 minutes at room temperature to obtain a 
pellet. I then resuspended the pelleted cells in 250µl P1 buffer and transferred it to a 
microcentrifuge tube. I then added 250µl P2 buffer and mixed thoroughly by inverting 
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the tube 4-6 times until the solution became clear. I then added 350µl of N3 buffer and 
mixed immediately by inverting the tube 4-6 times. I then centrifuged for 10 minutes at 
17,900 x g in a table-top microcentrifuge. The supernatant was added to the QIAprep 
column and centrifuged for 60 seconds and the flow through decanted. I then washed 
the QIAprep spin column by adding 750µl PE buffer and centrifuged for 60 seconds and 
again discarded the flow through. This was followed by centrifuging the spin column for 
1 minute to remove residual wash buffer.  I then placed the column in a clean 1.5ml 
microcentrifuge tube and I eluted the LUC-3’UTR by adding 50µl of EB buffer to the 
centre of the QIAprep spin column and let it stand for 1 minute and centrifuged it for 1 
minute.  
 
On confirming the authenticity of the LUC-3’UTR by examining their sequence, I purified 
them from the bacteria using Qiagen maxiprep purification protocol. This involved 
harvesting the bacteria cells by centrifugation at 6000 x g for 15 minutes at 4°C. The 
bacteria pellet was then resuspended in 10mls of P1 buffer to allow complete mixing of 
lysis buffer by vortexing. I then added 10mls of P2 buffer and mixed gently by inverting 
4 times and incubating at room temperature for 5 minutes.  I then added 10mls of chilled 
(to enhance precipitation) P3 buffer and mixed immediately by inverting 4 times and 
incubated on ice for 20 minutes. I then centrifuged at 20,000 x g for 30 minutes at 4°C 
and removed the supernatant containing plasmid DNA promptly. I centrifuged the 
supernatant again at 20,000 X g for another 15 minutes at 4°C again removing the 
supernatant. I equilibrated a Qiagen tip 500 by applying 10mls QBT buffer and allowed 
the column to empty by gravity flow. I then applied the supernatant to the tip and 
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allowed it to enter the resin by gravity flow. I then washed the Qiagen tip with 2 X 30mls 
QC buffer to remove all contaminants and eluted the Luc-3’UTR vector with 25mls of 
QF buffer. The vector was the precipitated by adding 10.5 ml isopropanol and mixed 
and centrifuged at 20,000 x g for 30minutes at 4°C, carefully decanting the supernatant. 
I washed the DNA pellet with 5mls of 70% ethanol and centrifuged at 20,000 x g for 10 
minutes carefully decanting the supernatant without disturbing the pellet. The pellet was 
air dried and redissolved in 400µl of T.E. buffer and stored at 4°C. The concentrations of 
the vectors were measured by spectrometry using the Spectrophotometer Ultrospec 
3100 Pro. 
 
Transfection of pmir GLO vector and assessment by Luciferease reporter assay 
The cells lines were transfected with both the Luc-3’UTR (vector construct) and Luc- 
control (pmirGLO vector only) following the invitrogen transfection protocol. Firstly the 
cells were plated using a specific number of cells (counted with the aid of a 
haemocytometer) per well of a 96 well plate and were incubated overnight with medium. 
On the second day I made a mixture of 200ng of vector in 25µl of opti-mem and 0.5µl of 
lipofectamine in 25µl of opti-mem and left to stand for 20 minutes. I then removed the 
medium from the well and added vector lipofectamine mixture to each well plus another 
25µl of opti-mem to each well. This was left for 6 hours in the incubator and then 
replaced the opti-mem mixture with 75 µl of medium and kept in an incubator for 
48hours.   
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I then assessed the transfection by measuring the expression of the luciferase after the 
addition of Dual Glo luciferase reagents according the promega Dual Glo luciferase 
assay system protocol as follows; I removed the 96 well plates from the incubator and 
added 75µl of Dual Glo luciferase reagent (an equal volume to the medium) to each well 
and mixed. I waited for 10 minutes then measured the firefly luminenscence. To 
measure the Renilla luciferase activity I then added 75µl of Dual Glo Stop and Glo 
reagent (ratio 1:100) to each well and mixed. I waited at least 10 minutes and then 
measured the luminescence. I then normalized the reaction by the ratio of the luciferase 
firefly to renilla activity. I measured the luminescence using the Wallac 1420 
Luminometer. The effect of the presence of the 3’UTR on luciferase expression was 
determined by comparing the luciferase activity of cells transfected with the Luc-3’UTR 
and control Luc constructs.  A schematic diagram of the effect of differing interactions 
with and without the plexin B1 3’UTR is shown below in figure 12 below.  
 
Figure 12 
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QPCR and Transcriptome array experiments 
Quantitative polymerase reactions (qPCR) were carried out to verify and quantify the 
levels of expression of Plexin B1 in the transcriptome array experiments, in cell lines on 
their own as well as in cell lines transfected with mimics. In each case these reactions 
were done in triplicates to obtain a more accurate value. I used the eppendorph 
Mastercycler realplex machine to perform these reactions. The parameters for the 
programme were set as shown in table 4 below; 
Table 3: The PCR parameters 
Programme Step Temperature (°c) Time (mm:ss) Cycles 
Heat Activation 1 95.0 03:00 1 
PCR cycle 2 
3 
95.0 
57.0 
00:05 
00:08 
 
Melt Curve 4 
5 
6 
7 
95.0 
60.0 
 
95.0 
00:03 
00:15 
20:00 
00:15 
1 
 
 
 QPCR transcriptome array was performed to detect the microRNAs (miRNAs) that 
regulate Plexin B1expression. Prior to performing the transcriptome arrays the QPCR 
reactions were optimized. Optimisation experiments included performing different 
QPCR reactions to ascertain which dye would be the most suitable for the transcriptome 
array from either Taqman or SYBR green dyes. SYBR green was chosen as it worked 
well with good CT values and was recommended by Qiagen the makers of the 
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transcriptome PCR array. The optimisation process also included performing qPCR 
using cDNA initially from cancer cell lines, then later cDNA from Hela cells to closer 
resemble the QPCR of the transcriptome array (this array uses Hela cells). Another part 
of the optimization process was to perform qPCR using different annealing 
temperatures to find which temperature best suited the primers and probes. After 
optimization qPCR was performed in the Mastercycler realplex machine with SYBR 
green dye using Qiagen Sure FIND transcriptome PCR arrays to identify potential 
miRNA that regulate Plexin B1. Primers for Plexin B1, and GAPDH were used for the 
qPCR process.  The array contains Hela cells transfected with miRNA mimics and also 
controls consisting of Hela cells without miRNA mimics.  The relative levels of 
expression of Plexin B1 in Hela cells with the mimics relative to those without were 
quantified and normalised using the housekeeping gene Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as control. 
 
In the other qPCR experiments (not involving the transcriptome array), I also performed 
optimisation experiments finding again SYBR green to be the dye of choice. I used the 
cDNA samples obtained from the first strand synthesis for these reactions, after they 
were diluted to a ratio of 1 in 5. For each reaction to make a total of volume 20µl per 
well, I used10µl of Brilliant III Ultra-Fast SYBR green qPCR master mix, 6µl of nuclease 
free water, 1µl of both sense and antisense primers and 2µl of the diluted cDNA 
sample. I used three housekeeping genes GAPDH, B2M and Succinate Dehydrogenase 
(SDHA) for controls in these experiments. These samples were placed in a 96 well plate 
and the qPCR reaction done in the eppendorph Mastercycler realplex machine.  
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Co transfection of miRNAs and pmir GLO Vector experiments 
The Candidate miRNAs were transfected into prostate cancer cell lines to assess their 
effects on the plexin B1 3’UTR found on the vector construct. The miRNAs were 
transfected into the cells along with LUC- 3’UTR (pmir GLO vector construct), or with 
LUC-Cont (pmirGLO vector alone). The co-transfection was done using the Qiagen 
transfection protocol database for cotransfection of Plasmid and miRNA(Qiagen). Using 
the fastforward cotransfection of the cell line protocol. For each well I seeded 4 X 106 
cells into the 96 well plate in 100µl in culture medium and then incubated them for a few 
minutes at 37°C at 5% CO2. I then diluted 0.2µg of vector (either Luc-control or Luc-
3’UTR) in 50µl of opti-mem. I then added 1.6 ρmol of miRNA mimic to the diluted vector 
and mixed. I added 0.75µl attractene transfection reagent to the diluted vector and 
mixed. The mixture was then incubated for 15 minutes at room temperature to allow 
formation of tranfection complexes. I then added the complexes drop wise onto the cells 
in the 96 well plates and gently swirled the plate to allow uniform distribution. I 
incubated the cells with the transfection complexes for 48 hours. Then I analysed the 
results using the Dual GLO luciferase reporter assay system. 
 
Transfection control experiments and transfection of miRNAs into the cell lines 
I then proceeded to assess the effect of microRNAs on the expression levels of plexin 
B1 in the cell lines by transfecting the candidate miRNAs into the cell. In order to 
confirm transfection I conducted transfection control experiments by transfecting siRNA 
(All Star HS Cell Death Control siRNA) into cell lines following the Qiagen transfection 
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protocol database for the specific cell line(Qiagen) using PBS and water as control. 
After following the transfection steps as explained below in the miRNA transfection 
paragraph, I monitored the effects of transfection in the cells by placing the 6 well plate 
in an Incucyte imaging system taking images every 4 hours up to 56 hours to assess 
the changes in each well. 
 
To transfect the miRNAs into the cells I followed the Qiagen transfection protocol 
database for the specific cell line (Qiagen). The steps were as follows; I seeded 2 x 105 
cells per well of a 6-well plate in 2300µl of culture medium and then incubated them for 
a few minutes at 37°C at 5% C02. I then diluted 150ng miRNA in 100µl Opti-mem and 
added 24µl of HiPerfect transfection reagent and mixed the resultant mixture. The 
mixture was then incubatedfor 15 minutes at room temperature to allow formation of 
tranfection complexes. I then added the complexes drop wise onto the cells in the 96 
well plate and gently swirled the plate to allow uniform distribution. I incubated the cells 
with the transfection complexes for 48 hours. The total RNA in the transfected cells are 
then extracted using the Qiagen RNeasy mini handbook protocol. I then analysed the 
levels of plexin B1 RNA in these transfected cells by performing qRT-PCR. 
 
Analysis of plexin B1 protein levels in cells transfected with miRNA 
In order to assess the plexin B1 protein levels in the cell lines transfected with miRNA I 
followed the following step; I first extracted the protein, then measured the concentration 
of the protein, I performed SDS-PAGE and protein blotting and finally western blotting 
and the films were developed with aid of developer and fixer.   
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Protein extraction 
To extract the protein I made use of Oinuma lysis buffer containing added inhibitors. A 
100mls of lysis buffer consisted of 100mls of nuclease free water containing 2mls of 
20mM Tris pH 8, 15ml of 150mM NaCl, 0.4mls of 4mM MgCl2, 1ml of 1% NP40 and 
10mls of 10% glycerol. To 1ml of the lysis buffer I added the following inhibitors; 10µl of 
1mM PMSF (phenylmethylsulphonyl fluoride), 10µl of 10µg/ml Leupeptin, 20µl of Na 
Vananadate, 20µl of Na Flouride and 10µl of Pepstrate. I first suctioned off the medium 
from the wells of the 6 well plates.  I washed the cells with 2mls of ice cold PBS and 
after suctioning off the PBS I added 100µl of lysis buffer to each well and left on ice for 5 
minutes. The cells were then scraped off using a cell scraper and the cell lysate was put 
into a 1.5ml eppendorf tube on ice for 15 minutes. I then centrifuged the tube at 13,000 
rpm for 10 minutes at 4°C. I then collected the supernatant in a pre-chilled eppendorf 
tube.   
 
Measurement of protein concentration 
The protein concentration was calculated using the lowry method. The protein 
concentrations were normalised using the lowry protein assay kit. Serial dilutions of 
Bovine Serum Albumin (BSA) were made from the BSA standard solution. A standard of 
water 200mls volume in a tube was used as baseline control (the blank). I made a serial 
dilution of varying concentrations of BSA in 5 tubes as follows in the table 5 below; 
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Table 4: BSA dilutions  
Tube Content Concentration 
1 33.3% of BSA in 200µl 0.5mg/ml 
2 16.7% of BSA in 200µl 0.25mg/ml 
3 8.3% of BSA in 200µl 0.125mg/ml 
4 4.2% of BSA in 200µl 0.0625mg/ml 
5 2.1% of BSA in 200µl 0.03125mg/ml 
 
The process of dilution involved adding 125µl of BSA into 375µl of water in a 10ml tube 
then decanting 200µl of the resultant mix into another 10ml tube ( tube 2) containing 
200µl of water and mixed by vortexing. 200µl of the resultant mix from tube 2 was 
decanted into tube 3, which contains 200µl of water. This process was repeated till tube 
5 was made and then 200µl from tube 5 is discarded. I also discarded 100µl from tube 1 
to make a final volume of 200µl for each tube. I then diluted 10µl of each lysate (protein 
extract) sample 20 folds with 190µl of water. This was followed by preparing the Folin-
Ciocalteu reagent by diluting 2N Folin-Ciocalteu reagent with distilled water to make a 
1N solution. With the aid of a timer I added 1ml of modified lowry protein assay reagent 
to each diluted BSA sample and standard and mixed by vortexing gently at 20 second 
intervals per reaction. The mixture was incubated for exactly 10 minutes at room 
temperature from the start of the first reaction in tube 1. I intiated the stop reaction at the 
end of the 10minutes by adding 100µl of 1N Folin-Ciocalteu reagent and mixed gently 
by vortexing. The samples were then incubated for 30 minutes at room temperature and 
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the concentration were measured using the UV/ visible spectrophotometer Ultrospec 
3100 Pro. The standard curve was plotted automatically by the machine based on 
absorbance reading against the concentration of BSA standards. I multiplied the reading 
of each sample by 20 to get the protein concentration (as the lysate was diluted 20 
folds).   
 
SDS-PAGE and protein blotting 
An equal amount of total protein from the lysate samples were normalised to the same 
volume using lysis buffer. I heated the mixture at 95°C for 5 minutes and the denatured 
protein samples were loaded onto the sodium dodecyl-sulphate (SDS)- polyacrylamide 
gel with appropriate concentration of acrylamide. I made the 8% resolving gel by mixing 
the following; 3.75mls of 1M Tris pH 8, 2.67ml of 30% acrylamide, 3.53mls of water, 
50µl of 20% SDS, 100µl of ammonium persulfate (APS), 6µl of TEMED. The solution 
was poured onto plates on the assembled chamber and 70% ethanol was added onto 
the top and left to set for an hour. To make the stacking gel I made the following; 375µl 
of 1M Tris pH 6.8, 374µl of 30% acrylamide, 2.24ml of water, 15µl of 20% SDS, 30µl of 
10% APS, and 5µl of TEMED. I poured off the ethanol from the chamber and added the 
stacking gel solution, placed the comb and left to set for 20 minutes. After the gel had 
set I loaded an equal amount of protein per well and I also loaded to one well a rainbow 
molecular marker to a well as a size reference. The chamber was filled with running 
buffer then I proceeded with electrophoresis firstly with 66V till the junction of the 
stacking and resolving gel was reached and 94V thereafter until the dye reached the 
end of the gel. 
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Western blotting 
I then proceeded to perform western blotting. This was done by first separating the 
plates to expose the gel and the stacking gel section was discarded. The sponges are 
soaked in transfer buffer and the gel was rinsed in transfer buffer. The polyvinylidane 
fluoride (PVDF) membrane was prewashed in 100% methanol and then rinsed in 
transfer buffer and placed straight onto the gel removing any bubbles that may have 
formed on the surface. Filter paper was then placed on the PVDF membrane again 
removing any bubbles. A second filter paper was then placed on the initial filter paper 
and I then flipped this set up to reveal the gel onto a presoaked sponge.  To complete 
the sandwich I added onto the gel 2 filter papers and another soaked sponge and 
secured the sandwich in a cartridge. The cartridge was placed into the mini trans-blot 
cell of Bio-Rad filled with transfer buffer and electrotransfer was performed overnight at 
36V. 
 
Figure 13: A Schematic diagram of a Western blott transfer sandwich 
 
 sponge 
   ___________________________________________ Filter paper X 2 
                 Gel 
      PVDF 
  ___________________________________________ Filter paper X 2 
   sponge 
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After the electrotransfer I rinsed the membrane briefly in PBS-Tween 20 (PBS-T), 0.1% 
Tween-20 in 1 X PBS. I then blocked the PVDF membrane with 5% non-fat milk ( 5g in 
100mls of PBS Tween FOR ≥ 1 hour at room temperature. After blocking, the 
membrane was probed with 10mls of 1% non-fat milk containing diluted primary 
antibody (3µl of plexin B1, 1µl of actin antibody as appropriate). The membrane was 
then washed four times with PBS-T for 4 minutes each time. After washing the 
membrane was incubated with 1µl of appropriate horseradish peroxide conjugated 
secondary antibody diluted in 10mls of 1% non-fat milk for 1 hour.  The membrane was 
then washed in again in PBS-T four times for 4 minutes each time and was then ready 
for enhanced chemiluminescent development. The chemiluminescent signals were 
developed by Pierce ECL western blotting substrate. An appropriate volume of mixture 
of detection reagent 1 and 2 at ratio 1:1 was added to the membrane and incubated for 
5 minutes at room temperature. The membrane was then placed between 2 sheets of 
film and set into Kodak biomas cassette. The membrane was exposed to a film and the 
films were developed with Kodak Developer and Fixer solution. 
 
 
Statistical analysis 
 
All cell line experiments were performed in triplicates to improve the validity of the 
results. Statistical analysis and significance were assessed with aid of SPSS 20, Origin 
and Microsoft Excel.  
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Chapter 3 
 
 
Plexin B1 full length and variants 
expression in cell lines 
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Introduction 
The receptor plexin B1 has been found in various organs of the body such as in blood 
cells, blood vessels and brain where it plays an important part in the early development 
of these areas. It also has a role in the normal functions of the body for instance in the 
immune system(Tamagnone et al., 1999, Nkyimbeng-Takwi and Chapoval, 2011). It has 
been shown that plexin B1 is present and expressed in varying amounts in different 
prostate cancer cell lines by Wong et al(Wong et al., 2007). What is not known is if all 
prostate cancer cell lines express plexin B1 and what the levels of expression of plexin 
B1 levels are in the cell lines.  
 
Plexin B1 has been shown to exist in different forms known as splice variants as shown 
by Tamagnone et al(Tamagnone et al., 1999). There have been more variants predicted 
to exist by online genome databases that have yet to be verified in the literature(NCBI, 
2011). These variants are likely to act differently to the known plexin B1 variants, for 
instance interact differently with local miRNAs because of their different nucleotide 
sequence composition, and as such are worth discovering because of the potential for 
different cellular effect. It is not known if any of the cell lines express the alternative 
variants; variant R and the truncated variant. 
 
The aim of this section of the investigation was to establish if prostate cancer cell lines 
express the full length variant version of plexin B1 mRNA. The next step was to 
investigate if these cell lines also expressed the two common alternative spliced 
variants in question, variant R and truncated variant. I started to find proof of the 
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existence of a variant of Plexin B1 by first seeking a plexinB 1 mRNA that lacked exon 
11 a common trend in both alternatively spliced variants(NCBI, 2011), the absent exon 
11 is highlighted in figure 14 below.  I then followed this up by looking for  transcripts 
with a shortened 3’UTR end equivalent to variant R and the Truncated variant. 
 
Fig 14: Schematic of variants of plexin B1 mRNA  
The diagram shows the variants of plexin B1, a the full length variant, b the variant R and c the truncated 
variant of plexin B1 courtesy of http://www.as3d.org/human2006/genePLXNB1.html and NCBI database 
 
 
 
 
Results 
 
The results are divided into the following sections 
1. The use of RT-PCR to measure plexin B1 mRNA expression in cell lines.  
2. The use of qRT-PCR to measure plexin B1 mRNA expression.  
3. Alternative splicing of of plexin B1 exon 11 experiments. 
4. The results of 3’RACE experiments for plexin B1 truncated variant and plexin B1        
            variant R. 
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1.The use of RT-PCR to measure plexin B1 mRNA expression in cell lines  
The first step in this project is to confirm the existence of Plexin B1 mRNA in the chosen 
9 cell lines. These cell lines are as follows; PC3, DU145, LNCaP, 1542CP, 1542NP, 
YUSIK, GCT27, T24 and 22RV1. The background and rationale for the use of these cell 
lines are covered in the second chapter. 
 
To achieve the first step of the investigation, to confirm the expression of Plexin B1, 
RNA was extracted using the Qiagen RNA extraction kit protocol from the following cell 
lines; PC3/27, DU145/71, Yusik10, GCT27/75, 22RV1/5,1542NP/51 and LNCaP/73. 
RTPCR was then performed using sense and antisense primers for Plexin B1 and the 
PCR products were run in gel electrophoresis. No bands were seen in the control of no 
cDNA ( not shown).The cDNA products were then cut out of the gel and sequenced. 
The products were confirmed to be Plexin B1 mRNA for the 7 cell lines by comparing 
the sequence of the RT-PCR products extracted from the gel with the reference 
sequence of Plexin B1 on the NCBI database using the BLAST computer program. This 
is as shown in the image of agarose gel electrophoresis shown in figure 15 below. 
See also the image of an electropherogram in figure 16 below; 
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Fig 15: Electrophoresis gel showing presence of plexin B1 mRNA in cell lines 
RNA from each cell line indicated was reversed transcribed and amplified by PCR and the products 
separated on an agarose gel for plexin B1 and the control GAPDH. 
 
 
Fig 16: section of electropherogram showing presence of Plexin B1 in a cell line 
DNA from the amplified products in Fig 14 was extracted from the gel and was sequenced by Sanger 
sequencing method ( representative electropherogram)
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2.The use of qPCR to measure plexin B1 mRNA expression plexin B1 levels 
 
In order to confirm the presence of plexin B1 in the cell lines, and to quantify the levels 
of expression of plexin B1, I performed a series of qRT-PCR experiments.  
 
To obtain actual and relative levels of expression of Plexin B1 mRNA in the following 
cell lines; T24, Yusik, 1542C, PC3, 22RV1, DU145, LNCaP, 1542NP, GCT, VCAP, 
LNCaPLN3, I used Quantitative PCR with SYBR Green dye. The extracted RNA from 
two different passages of the above cell lines, were converted to cDNA using the 
protocol of the first stage of Invitrogen superscript III first strand synthesis for RTPCR. 
The cDNAs were then used to perform QPCR using the SYBR Green dye with a set 
QPCR protocol. The experiment was performed 3 times, and the results show all cell 
lines express Plexin B1 and at different levels. The transcript copy number was 
calculated using standard of known copy number. It was shown that all cell lines 
expressed Plexin B1 with 1542CP expressing the highest amount as shown in the 
graph 2 below. LNCaP LN3 had a higher expression level than LNCaP and the other 
cell lines except 1542CP. 
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Graph 2: QPCR quantification of the level of expression of plexin B1 
The copy number of plexin B1 mRNA was measured by qPCR of cDNA using housekeeping cotrols 
GAPDH, B2M and SDHA. The mean of the 3 experiments calculated and the error bars represent 
the SEM. 
 
 
 
3. Alternative splicing of of plexin B1 exon 11 experiments 
To investigate if these cell lines also express the two alternative spliced variants in 
question, variant R and the truncated variant, I initially aimed to investigate whether the 
cell lines expressed variants of plexin B1 that lacked Exon 11. This was because the 
NCBI gene reference sequence database indicates that exon 11 of the Plexin B1 mRNA 
may be alternatively spliced and is not present in both the truncated variant and variant 
R (NCBI, 2011). I extracted RNA using the Qiagen RNA extraction kit protocol from the 
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following cell lines; PC3/27, DU145/71, Yusik10, GCT27/75, 22RV1/5, LNCaP, 
1542NP/51. I then performed RT-PCR using primers flanking exon 11 on the extracted 
RNA for each cell line. The cDNA PCR products were identified using agarose gel 
electrophoresis; they were cut out and sequenced to confirm their presence. The image 
of the agarose gel electrophoresis is shown in figure 17 below;   
Fig 17: The expression of plexin B1mRNA using exon 11 primers 
RNA from each the cell lines indicated was reverse transcribed to cDNA and amplified by PCR using 
primers flanking exon 11 of plexin B1. The products were separated on an agarose gel the band were 
subsequently cut out and sequenced. The same cDNAs were amplified in parallel using primers to 
GAPDH as a postive control. 
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As seen above most of the cell lines had at least four bands while there were two cell 
lines that each had an extra bands making 5 bands, these were PC3 and DU145. The 
bands that were common to all cell lines were equivalent to 3 sets of cDNA products of 
plexin B1 that were of  ~800bp, ~250bp and ~200bp in size. The smaller 250bp and 
200bp products, given their size, suggest they were the plexin B1 mRNAs that lacked 
exon 11. I confirmed these cDNA products by sequencing them using the Sanger DNA 
sequencing technique (provided by the UCL cancer institute, Eurofins Genomics or 
Beckman Coulter Genomics). The larger 800bp cDNA products contained the full 
sequence of exon 11 of Plexin B1. The 800bp band was found in all the cell lines tested 
therefore represents the plexinB1 transcript in which exon 11 is not spliced out. The 
band of approximately 250 baase pairs was identical to variant R sequence, in which 
part of exon 11 is spliced out. Thus this would be the first time that variant R mRNA, the 
~250bp band seen on the electrophoresis image, has been identified by RTPCR in 
prostate cancer cell lines. The band of approximately 200 base pairs was identical to 
the truncated variant sequence. The ~200bp band is 34 nucleotides smaller than the 
variant R in keeping with the small space that separates the bands. The other bands are 
non specific amplified products as shown by the Sanger DNA sequence, this includes 
the small band only common to PC3 and DU145 cell lines. 
 
 
An example is shown below of the nucleotide sequences of the ~800bp, ~250bp and 
~200bp bands from the cell line LNCaP. The sequence of the 200bp band ( truncated 
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version) is partially superimposed over the sequence of the 250bp band ( variant R). 
This is probably because the bands were so close together on the gel and so the 250bp 
band was contaminated with some of the 200bp band when the bands were cut out of 
the gel. Electropherograms are shown in the appendix. 
 
LNCaP 
Upper band: 766 nucleotides plexin B1 full length variant  
 
AGGCAATGATCTAATAGATAGACCGATTTTTCCTAACTGGCGTTTTTGGCACCACC
AGAGCACCCACAAAGCCTCTTGTGATGCTGGGCCCATGGTTGCAAGCCATCATAG
CCCGCTTGTCTCCCCAAACCCTCCTGCAAGAGGTGGACCCAGCCCCTCCCCACCC
ACAGCCCCAAAAGCCCTGGCCACCCCTGCTCCTGACACCCTTCCCGTGGAGCCTG
GGGCTCCCTCCACAGCCACAGCTTCGGACATCTCACCTGGGGCTAGTCCTTCCCT
GCTCACCCCCTGGGGGCCATGGGCAGGTTCTGGCTCCATATCTTCCCCTGGCTCC
ACAGGGTCGCCTCTCCATGAGGAGCCCTCCCCTCCCAGCCCCCAAAATGGACCTG
GAACCGCTGTCCCTGCCCCCAATGACTTCAGACCCTCAGCCACACCTGAGGACCT
CTTGGCCTCCCCGCTGTCACCGTCAGAGGTAGCAGCAATGCCCCCTGCAGACCCT
GGCCCCGAGGCTCTTCATCCCACAGTGCCCCTGGACCTGCCCCCTGCCACTGTTC
CTGCCACCACTTTCCCAGGGGCCATGGGCTCCGTGAAGCCCGCCCTGGACTGGC
TCACGAGAGAAGGCGGCGAGCTGCCCGAGGCGGACAAGTGGACGGGGGGTGAC
GCACCCGCCTTTCTCCACTTCCACCCTCCTCACAAGTGATGGAGACTCAGCAGAG
CTTGAGGGCCCTCCCGCCCCCCTCATCCTCCCGTCCAGCCTCGACTACCAGAA  
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LNCaP 
250bp band: plexin B1 variant R 
GTGCCGGCCTGTGTGAGCAGCCGCTGGGGGTGTAACTGGTGTGTCTGGCAGCAC
CTGTGCACCCACAAGGCCTCGTGTGATGCTGGGCCCATGGTTGCAAGCCA T C A 
G A/G T/G G/C A/C C/T G G/C A/T T/G G/A C/T C/T C/T A/C G/C C C/A A/G A/G  A/G 
C T/C T/C 
 
LNCaP 
200bp band: plexin B1 truncated variant  
 
CTTTGAACAGGACTGTGTGAGCAGCCGCTGGGGGTGTAACTGGTGTGTCTGGCAG
CACCTGTGCACCCACAAGGCCTCGTGTGATGCTGGGCCCATGGTTGCAAGCCATC
AGGTGATGGAGACTCAGCAGAGCTTGAGGGCCCTCCCGCCCCCCTCATCCTCCC
GTCCAGCCTCGACTACCAGA 
 
 
The purple coloured nucleotides are missing in the 200bp band and have therefore 
been spliced out and indicate the missing exon 11. The experiment was done in 
triplicates for the cell lines using the next passage of cells to confirm the presence or 
absence of Exon 11. The results of these experiments show that all cells have at least 
three forms of plexin B1 i.e with or without Exon 11 and two different splice variatns. I 
also checked the sequence for these specific variants using the NCBI genome 
database. I was able to confirm the existence of plexin B1 truncated variant due to its 
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sequence in all the cell lines. These were the smaller 200bp band as expected. An 
example is shown below; 
Truncated variant reference sequence from NCBI 
 
     1801 agaggagccg actacgtatc cgtgagcgtg gagctcagat ttggcgctgt tgtgatcgcc 
     1861 aaaacttccc tctctttcta tgactgtgtg gcggtcactg aactccgccc atctgcgcag 
     1921 tgccaggcct gtgtgagcag ccgctggggg tgtaactggt gtgtctggca gcacctgtgc 
     1981 acccacaagg cctcgtgtga tgctgggccc atggttgcaa gccatcaggt gatggagact 
     2041 cagcagagct tgagggccct cccgcccccc tcatcctccc gtccagcctc gactaccagt 
     2101 atgacacccc cgggctctgg gagctggaag aggcgacctt gggggcaagc tcctgcccct 
     2161 gtgtggagag cgttcagggc tccacgttga tgccggtcca tgtggagcgg gaaatccggc 
     2221 tgctaggcag gaacctgcac cttttccagg atggcccagg agacaatgag tgtgtgatgg 
     2281 agctggaggg cctcgaggtg gtggttgagg cccgggtcga gtgtgagcca cctccagata 
     2341 cccagtgcca tgtcacctgc cagcagcacc agctcagcta tgaggctctg cagccggagc 
 
The truncated splice variant has a different 5’splice site from the variant R, resulting in 
the splicing out of an additional 34bp. This results in a shift in reading frame and 
premature termination of translation, as shown below: 
TGAT GCT GGG CCC ATG GTT GCA AGC CAT CAG GTG ATG GAG ACT CAG CAG 
AGC TTG AGG GCC CTC CCG CCC CCC TCA TCC TCC CGT CCA GCC TCG ACT 
ACC AGTATG ACA CCC CCG GGC TCT GGG AGC TGG AAG AGG CGA CCT  
TGG GGG CAA GCT CCT GCC CCT GTG TGG AGA GCG TTC AGG GCT CCA CGT 
TGA 
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The resultant truncated protein has amino acids 730-2135 missing and amino acids 
677-729 are changed. The mRNA is 3,863bp, and the protein is 729 amino acids long.  
The splicing out of part of exon 11 in variant R does not result in a frameshift. Variant R 
produces a protein twhich has amino acids 688-870 missing to give a protein of 1952 
amino acids.The agarose gel shows that the truncated variant is expressed at higher 
levels than variant R. 
 
 
LNCaP 
200 bp band: 184 nucleotides plexin B1 variant  
CTTTGAACAGGACTGTGTGAGCAGCCGCTGGGGGTGTAACTGGTGTGTCTGGCAG
CACCTGTGCACCCACAAGGCCTCGTGTGATGCTGGGCCCATGGTTGCAAGCCATC
AGGTGATGGAGACTCAGCAGAGCTTGAGGGCCCTCCCGCCCCCCTCATCCTCCC
GTCCAGCCTCGACTACCAGA 
The red letters indicate identical sequences, therefore showing that the smaller 200bp 
LNCaP band was in keeping with the truncated variant.
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4.The results of 3’RACE experiments for plexin B1 truncated variant and plexin 
B1 variant R 
The next set of experiments undertaken was to confirm the presence of the truncated 
variant and variant R, using the 3’RACE protocol provided by Invitrogen as discussed in 
the second chapter. This was to search for a shortened 3’UTR end equivalent to variant 
R and the truncated variant. The cDNA products extracted from the gel electrophoresis 
as shown in figure 18 and 19 below, were sent for DNA sequencing. The analysis only 
showed the full 3’ UTR end which is present in the known full length variants 1 and 2 
and did not reveal the existence of a shortened 3’UTR thought to be contained in 
Variant R
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Fig 18: Agarose gel electrophoresis of 3’RACE experiments in 6 cell lines 
The Electrophoresis gel shows the expression of plexin B1 3’UTR region as determined by 3”RACE 
studies in the cell lines YUSIK, PC3, DU145, LNCaP, 1542NP. No shortened 3”UTR was found. 
 
   YUSIK      PC3        DU145     1542C    LNCAP     1542NP      RNA     No RNA      1kb + Ladder 
                                                                                                  control      control      
 
 
  
Fig 19: Agarose gel electrophoresis of 3’RACE experiments in 3 cell lines 
The Electrophoresis gel shows the expression of plexin B1 3’UTR region as determined by 3”RACE 
studies in the cell lines 1542NP, 22RV1 and GCT. No shortened 3’UTR was found. 
1542NP            22RV1          GCT27              1KB+ Ladder 
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Discussion 
 
Plexin B1 is an important receptor involved in the embryonic development and in the 
normal physiological process of the body due to the interaction with its ligand Sema 4D.  
It has been shown to occur in normal body tissue and studies have shown its existence 
in cancer cells. My first task was to use rtPCR to generate and multiply cDNAs from the 
extracted cellular RNA. I confirmed that all the cell lines did indeed express plexin B1 
mRNA and I was able to show through quantitiative PCR that plexin B1 was expressed 
at differing levels in the cell lines. It has previously been shown by Wong et al (Wong et 
al., 2007) that plexin B1 was highly expressed in LNCaP cells compared to PC3 cells 
and this was confirmed in this study. I was able to show for the first time that it is even 
more highly expressed in LNCaP LN3 cells and showed its varying levels in more cell 
lines such as VCaP. It has already been shown that plexin B1 expression is increased 
in prostate cancer and it has been suggested that it may have a role in the metastasis of 
the disease. It would appear that these expression levels might lend credence to its role 
in metastasis. LNCaP LN3 cells were generated by orthotopic transplantation of LNCaP 
into nude mice, followed by the serial (3x) orthotopic transplantation of the lymph node 
metastasis produced. LNCaP LN3 have a higher level of plexin B1 than LNCaP, 
suggesting that plexin B1 expression may contribute to metastasis in LNCaP cells in 
vivo. LNCaP was derived from prostate cancer lymph nodes and DU145 brain 
metastasis. These two aforementioned cell lines have a higher level of expression that 
PC3 cells that were derived from prostate cancer bony involvement.  
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Then section 3 of my study in this chapter confirms the existence of splice variants of 
plexin B1. The resultant protein products of these variants are likely to have different 
functions and their expression may be linked to prostate cancer metastasis. The full 
length variants of plexin B1 mRNA have a complete 3’ UTR which can be regulated by 
miRNAs. The truncated variant and variant R plexin B1 mRNAs lack 3’UTR or 
incomplete 3’UTR respectively. Therefore their expressions is not likely controlled by 
miRNAs and this may be the link to their levels of expression in prostate cancer.  
 
Tamagnone and colleagues (Tamagnone et al., 1999) have already discussed the 
existence of the truncated variant and my study has confirmed their findings. I was able 
to show in the cell lines PC3/27, DU145/71, Yusik10, GCT27/75, 22RV1/5, LNCaP, 
1542NP/51 that a version of plexin B1 without exon 11 does exist due to splicing.  On 
analysis of the nucleotide sequence of the smaller 200bp product I was able to confirm 
it was the truncated variant of plexin B1. Tamagnone and the NCBI genome database 
have shown that this variant is translated to protein. The protein lacks a transmembrane 
domain and an intracellular domain. This truncated variant of plexin B1 may act a 
dominant negative protein as it is predicted to bind to SEMA 4D but lacks an 
intracellular domain to transduce the signal. In addition evidence on the NCBI database 
showed that variant R, which has most of exon 11 spliced out, but no frame shift occurs 
and the rest of the protein is translated. I was able to show the existence of The Variant 
R, not mentioned by Tamagnone,  though mentioned on the NCBI databases but 
hitherto not shown in the literature. This discovery was aided by the use of the exon 11 
primers and the use of 3% agarose gel to separate out these bands that are quite 
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similar in size. The significance of this variant R is potentially a different function from 
the other proven variants of plexin B1 and is worth further analysis in future. PlexinB1 
contains an insertion of 230 amino acids within PSI-2 domain. This insertion is not 
present in other plexins and is predicted to be heavily O-glycosylated and is similar in 
sequence to mucin domains. Mucins are heavily glycosylated and are components of 
many gel- like secretions. Exon 11, which is spliced out in both variants described here, 
encodes part of this mucin-like inserted sequence. 
 
I then went on to discover if any of the cell lines expressed plexin B1 with shortened 
3’UTR end as has been suggested in the NCBI genomic database(NCBI, 2011). I was 
not able to find a shortened plexin B1 3’UTR using the 3’RACE system. Although these 
results indicate that transcripts with a shortened 3’UTR are not transcribed in the cell 
lines tested, these variants may occur in other cell lines or primary prostate cancer 
tissue. This may be the case as it has been suggested that the truncated variant lacks a 
full 3’UTR end.
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Chapter 4 
 
 
 
Effect of 3‘ untranslated region (UTR) of 
plexin B1 on the expression of a reporter 
gene 
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Introduction 
The effect microRNAs ( miRNAs) have on gene expression is mainly through the 
inhibition of translation or the breakdown of mRNA transcripts. This effect is mainly due 
to the complementary binding of the seed region of the microRNA (usually at the very 
start of its 5’UTR), to the 3’UTR of the mRNA. It is known that microRNAs can be 
tumour suppressors and recent studies have shown that microRNAs have this function 
in prostate cancer(Qiang et al., 2011). Plexin B1 is a transmembrane receptor for 
semaphorin 4D that act as chemotactic cues for cell migration. There is overexpression 
and mutation of Plexin B1 in prostate tumours that suggests Plexin B1 has a role in 
prostate cancer and is a potential target for therapy perhaps by microRNAs mimics. 
Studies have shown the effect of plexin B1 overexpression in prostate cancer cells in 
vitro, whether through the transduction of the gene using a lentivirus or tansfection into 
a cell of interest (Zhou et al., 2012, Wong et al., 2007). What is yet to be determined is if 
the overexpression of plexin B1 in prostate cancer in vivo results from the aberrant 
regulation of expression via the 3’UTR of plexin B1. The aim of this section of the study 
was to determine if expression of plexin B1 is controlled by its 3’UTR section. 
 
Transfection is the process of introducing a foreign genetic material into an animal cell. 
In order to assess the effect of the plexin B1 3’UTR on gene expression, I cloned the 
3’UTR of plexin B1 downstream of a luciferase gene to generate a LUC-plexin B1 
3’UTR reporter construct. I carried out a series of transfection studies introducing this 
reporter construct into the cell lines and assessed the influence the plexin B1 3’UTR on 
expression of the luciferase  relative to luciferase expression of a control construct 
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lacking the 3’UTR of plexin B1. A renilla luciferase reporter construct was co-trasfected 
with the LUC-3’UTR or LUC-control construct to control for transfection efficiency. If we 
have a reduction in luminescence of the vector-construct (Luc-3’UTR) compared to the 
control construct (Luc-control) it means that there has been reduced mRNA translation 
of luciferase due to the presence of the 3’UTR of plexin B1.  These co reporter genes 
are used because renilla luciferase acts as a control. If there was a generalised 
downward effect on the cells such as cell death, the expression both reporter assays 
would be reduced relative to renilla expression. In this way I was able to more 
accurately determine the effects of the Luc-3’UTR. I calculated the ratio of the 
luminescence of firefly to luminescence of renilla to standardise the reaction. 
 
I first cloned the 3’UTR of the plexin B1, amplified by RACE into the luciferase reporter 
vector, making the construct LUC-3’UTR. The method has been described in the 
materials and method section in the second chapter. I then transfected this vector-
costruct versus control into my chosen cell lines PC3, LNCaP, 1542C, DU145, T24 and 
GCT and assessed the effect of the 3’UTR end. As shown in the schematic diagram 
below in figure 19, if the 3’UTR section of plexin B1 is actively repressed by potential 
microRNAs then there would be reduced activity of the reporter gene.  
 This transfection was done in triplicates each time, using 3 wells of a 96 well plate for 
Luc-control, 3 wells of a 96 well plate for Luc-3’UTR and 3 wells for no DNA controls. 
These experiments were repeated three times each times with 3 wells each to increase 
the accuracy of the final results. See the schematic diagram in figure 21.  
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Fig 20: The effect 3’UTR on the reporter gene expression 
Schematic diagram showing the effect of transfection of the vector construct into cell lines diagram 
modified from  pmirGLO Dual-Luciferase miRNA Target Expression vector protocol. 
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Fig 21: Schematic diagram of the transfection in triplicates 
21a 
 
21b 
Schematic of 96 well plates with triplicates 
 
3 x
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Results 
 
 
The results are described as follows; 
i- The results of plasmid vector-construct cloning experiments. 
ii- The results of transfection of cloned vector-construct versus control vector    
(including luciferase) experiments.
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1.Plasmid vector cloning experiments 
I successfully cloned the 3’UTR of plexin B1 into the plasmid vector creating a vector-
construct containing the 3’UTR region of the plexin B1 downstream of the luciferase 
gene. The detailed methodology can be seen in the second chapter. I achieved this by 
first amplifying the 3’UTR of plexin by 3’RACE, cutting out the amplified product from an 
agarose gel and ligating this into the cut vector. I then replicated the construct by 
transforming E.coli and growing up the transformed bacteria. The plasmid was extracted 
from the bacteria and the DNA analysed by performing gel electrophoresis. This 
electrophoresis showed the supercoiled crescent like band, which is the particular type 
of band seen when an intact circular plasmid is run on an agarose gel.  The cDNA 
sequences were sent for analysis.  This gel electrophoresis is seen below in figure 22. 
Fig 22: Agarose gel electrophoresis of the plasmid vector-construct 
The image shows two crescent like band confirming the presence of the vector construct, luc-3’UTR 
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The cDNA of the plasmid vector was successfully extracted from the gel and sent for 
sequencing. The sequence and BLAST results as displayed by the NCBI database is 
shown below  
 
AD_B7_pGLOxhoS.ab1 
 
NCBI blast result: 
622 nucleotides  Homo sapiens plexin B1 (PLXNB1), transcript variant 1, mRNA 99% 
 
CTGACTTAGGCTTCGCCTGGCTGGGCAGCCCTGGAGCTCGGAGGAGAGGCCACC
TTCTTAGGTGCCTGTAGTGACTGACAAGCAGAGTTAGTGGAAGGTGACTCCCAGT
CTCCTGGTGGCTCTGGCCTCGGCCCTGCTGGATCCACCTCCTAGACCCGGGGCC
TCAAGGCTCATGGGGTAGTACCCAGCCTGCTCCCCGAGTCCAGCGACCCTGTGAC
ACCGGTCTGCAGGGAGTTGGGGACTAAGGGCTTCCAGAGAGTGGCTGGAAGAGA
CTCCAGGCCCCTGGGGAGACTGTACTGTTCCTGAACACTGGCCTTGGCCACACTG
GGATTCGGAGAGGAAGGAGGAGAGCCCCATGCTTCCTGTCTGCCTCCTCCACCAT
CCCTGACCTCAGTTGAGCTGCCTCTGGCCTTGTTGCTGCTGCCACATCCTAGGTCT
AAGAGTTGAACGCCTCTCCTAGGCCACTACAAACTGACCCCTCAGCAGGGCTGGC
TGCCACAGGGCTGCCCTGCCTCATAGGTAGCCATGGTGAGGGCTATCTGCTGCAG
GGGGGTCTTGGGGAGAGTGGTGACTCCATTGACCCAGCTTTTCATTAAAGGATAA
CACACTGTCTTAGAGGGGA 
 
 
 
2.Transfection of cloned vector-construct versus control vector   
 
 The next step in this section of the study was to transfect the cloned vector-construct 
(Luc-3’UTR) I made into the chosen cell lines. The cells were co-transfected with either 
the vectors Luc-3’UTR and the Renilla construct or Luc- control and the Renilla 
construct. The expression of the luciferase was assessed after the addition of Dual Glo 
luciferase reagents (following the protocol of the Promega technical manual of the Dual 
Glo Luciferase assay system) using a Luminometer. The effect of the presence of the 
3’UTR on Luciferase expression was determined by comparing the Luciferase activity of 
cells transfected with the Luc-3’UTR and control Luc constructs. The results show a 
difference in the effect of Luc- 3’UTR compared to the Luc-control across all cell lines 
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with a downward expression of the luciferase in cell lines transfected with Luc-3’UTR 
compared to Luc-control. This is shown in graph 3 below. This is the first time that it has 
been shown in prostate cancer cell line that the 3’UTR of plexin B1 mRNA has a direct 
effect on expression of the gene suggesting a role for miRNAs, which are known to bind 
the 3’UTR ends of mRNAs. As is necessary this stage of the investigation was done in 
triplicates.  Each time a different passage of cells (i.e a different batch of the same cell 
line) was used for the transfection experiment involving both the LUC-3’UTR and the 
LUC-Control. I analysed these set of results statistically,with the data being normally 
distributed, using a one way ANOVA test on the SPSS 20 programme. The results are 
as shown in graph 4. I found that in DU145 and LNCaP cells, there were statistical 
significance decrease in luminescence due to transfection of the vector-construct Luc-
3’UTR compared to the Luc-control with a P value of ≤ 0.05.
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Graph 3:  the effect of transfection of luc- 3’UTR versus luc-cont on cell lines 
The graph shows the effect of transfection of vector construct containing plexin B1 3’UTR compared to 
control vector lacking plexin B1 3’UTR in a single experiment across various cell lines 
 
Graph 4:  transfection of cell lines with LUC-3’UTR VS LUC-Control average 
The graph shows the effect of transfection after triplicate across various cell lines of vector construct containing plexin 
B1 3’UTR compared to control vector lacking plexin B1 3’UTR. There was a difference in the effect of transfected 
Plexin B1 Luc-3‘UTR compared to Plexin B1 Luc-control across the cell lines as shown by reduced luciferase activity 
(luminescence).  key * p ≤0.05 
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Discussion 
In this section of my work I was able to construct a plasmid vector that contained the 
plexin B1 3’UTR using set protocols and confirming my construct with the aid of cDNA 
sequencing. The process of making this plasmid vector involved cutting the plasmid 
vector with a restriction enzyme then attaching it to the 3’UTR of plexin B1 by ligation 
with a ligase to form the vector construct and then making multiple copies of them by 
multiplying the plasmid vector in treated E.coli bacteria.  
 
 It has been shown for the first time in prostate cancer cell lines that the 3’UTR of plexin 
B1 may have an effect on gene expression as exemplified by the reduced luminescence 
of the luciferase assay. In two cell lines DU145 and LNCaP this reduction is statistically 
significant with P ≤ 0.05. These results suggest that the 3’UTR of plexin B1 does have 
an effect on gene expression and it suggests that some high level of plexin B1 in 
prostate cancer may result from aberrant regulation of expression via this region of 
plexin B1. As miRNAs regulate genes mainly through the 3’UTR, I suggest that in 
prostate cancer cells plexin B1 may be regulated by miRNAs binding to this region. This 
potentially provides another avenue for treatment of prostate cancer by identifying these 
potential miRNA. In order to investigate this potential regulatory mechanism I carried out 
a series of studies in the next set of chapters.
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Chapter 5 
 
 
 
Assessment of the regulation of plexin B1 
expression by microRNAs 
117 
 
 
Introduction 
It is known that the microRNAs regulate normal gene expression and they have also 
been shown to be involved in carcinogenesis. MicroRNAs are able to act both as 
tumour suppressors as well as oncogenes. As it has been shown that plexin B1 acts in 
an oncogenic capacity in prostate cancer I decided to investigate whether microRNAs 
negatively regulate plexin B1. This negative regulator or tumour suppressor microRNA 
would act by inhibiting the activity of plexin B1 and thus eventually be a candidate for 
therapeutic intervention against prostate cancer. There has been no discovery so far of 
such a microRNA. A precedent has already been set but in the case of cervical cancer 
as mentioned earlier in the hypothesis section of chapter one. It was suggested that the 
role of plexin B1 as an oncogene was negatively regulated directly by microRNA 214 
(mir 214) in cervical cancer(Qiang et al., 2011). Therefore mir 214 was a good reference 
point for me to begin my search.  
 
To perform this task, which involved qPCR analysis of a transcriptome array containing 
cDNAs of Hela cells pretreated with cancer specific microRNA, I started off by 
optimising my qPCR reactions in order to get as accurate a result as possible. 
Optimisation experiments included performing different qPCR reactions to ascertain 
which dye would be the most suitable for the transcriptome array from either Taqman or 
SYBR green dyes. SYBR green was chosen as it worked well with good CT values and 
was recommended by Qiagen the makers of the transcriptome PCR array. The 
optimisation process also included performing qPCR using cDNA initially from cancer 
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cell lines, then later cDNA from Hela cells to closer resemble the QPCR of the 
transcriptome array 
This was because the array contained Hela cells. Another part of the optimization 
process was to perform qPCR using different annealing temperatures to find which 
temperature best suited the primers and probes. I then carried out the qPCR with SYBR 
green dye using Qiagen Sure FIND transcriptome PCR arrays to identify potential 
microRNA that regulate Plexin B1. On analysis of the optimization results GAPDH 
produced the best housekeeping gene results with a steady expression levels across 
the cancer microRNAs used in the array. The array contains Hela cells transfected with 
microRNA mimics and control Hela cells without microRNA mimics. Hela cells are 
treated with 90 cancer candidate microRNAs and also 6 controls. The relative levels of 
expression of Plexin B1 in Hela cells with the mimics relative to those controls without 
mimics were quantified and normalised using the housekeeping genes GAPDH. The 
data was analysed with the database software based on Microsoft Excel. This 
calculated the δδ CT fold change with significant values equivalent to those microRNAs 
that get above the cut off point of the log to -1 or 1 fold change. The figure 23 below 
shows a schematic diagram of the qPCR transcriptome process courtesy of Qiagen.  
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Figure 23: qPCR transcriptome analysis image courtesy of Qiagen 
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Results 
This section is divided into two parts as follows: 
 
1- The results of qPCR optimisation experiments.  
2- The results of miRNA qPCR transcriptiome experiments 
 
 
 
1.qPCR optimisation experiments 
As stated in the introduction the aim of this section of the experiment was to get an 
accurate a reading as possible by finding the best conditions for qPCR. It involved 
altering the annealing temperatures and trying different housekeeping genes.  The 
graphs in graph 5 and graph 6 below show the difference between the use of B2M and 
GAPDH as housekeeping genes. It can be seen that the B2M is further to the right of 
the curve than necessary further away from the control represented by the blue curve 
yielding higher CT values which reduces its accuracy. This indicates a low level of B2M 
expression in the cell line. It can be seen that GAPDH has good CT values indicating 
high expression closer to the left of the curve and nearer to the control blue curve and in 
further experiments to be shown in the next section yielded good steady readings. 
 
I settled on the parameters for the qPCR phases and cycles on the Mastercycler 
realplex qPCR machine as shown in table 4 in the qPCR methodology section in the 
second chapter.   
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Graph 5: B2M CT Curve      
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Graph 6: GAPDH CT curve 
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2.The miRNA qPCR transcriptiome experiments 
The Qiagen transcriptome array containing cDNA from Hela cells treated with 90 
candidate cancer genes and 6 controls, yielded clear results with steady expression 
levels of the housekeeping gene GAPDH. See table 5 for Plexin B1 and table 6 for 
GAPDH below. 
Table 5: qPCR of candidate miRNAs using plexin B1 primers 
 
Symbol Plate Position EXP1 EXP2 EXP3 Average SD 
hsa-miR-124 TCMB-201 D8 29.01 29.16 29.77 29.085 0.106 
hsa-miR-21 TCMB-201 D9 29.17 29.25 29.12 29.180 0.066 
hsa-miR-181d TCMB-201 D10 28.72 28.92 29.13 28.923 0.205 
hsa-miR-301a TCMB-201 D11 28.67 28.88 28.70 28.685 0.021 
hsa-miR-200c TCMB-201 D12 28.13 28.12 28.15 28.133 0.015 
hsa-miR-100 TCMB-201 E1 28.47 28.51 28.64 28.490 0.028 
hsa-miR-10b TCMB-201 E2 28.81 29.23 28.73 28.770 0.057 
hsa-miR-155 TCMB-201 E3 28.62 28.72 28.96 28.767 0.175 
hsa-miR-1 TCMB-201 E4 29.59 29.55 29.96 29.570 0.028 
hsa-miR-363 TCMB-201 E5 28.34 28.33 28.73 28.335 0.007 
hsa-miR-150 TCMB-201 E6 28.72 28.74 28.74 28.740 0.000 
hsa-let-7i TCMB-201 E7 28.91 29.01 29.35 28.960 0.071 
hsa-miR-27b TCMB-201 E8 28.60 28.60 28.57 28.600 0.000 
hsa-miR-7 TCMB-201 E9 28.58 28.87 28.71 28.720 0.145 
hsa-miR-127-5p TCMB-201 E10 28.71 28.86 28.76 28.777 0.076 
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Table 6: qPCR of candidate miRNAs using GAPDH primers 
 
 
 
 
 
 
 
 
 
        Symbol Plate Position   EXP1    EXP2     EXP3 Average SD 
hsa-miR-135b TCMB-201 D6 22.60 21.84 21.85 21.85 0.01 
hsa-miR-206 TCMB-201 D7 22.55 21.93 21.91 21.92 0.01 
hsa-miR-124 TCMB-201 D8 22.95 22.47 22.32 22.40 0.11 
hsa-miR-21 TCMB-201 D9 22.87 21.95 22.11 22.03 0.11 
hsa-miR-181d TCMB-201 D10 22.34 21.69 21.69 21.69 0.00 
hsa-miR-301a TCMB-201 D11 22.67 21.73 21.74 21.74 0.01 
hsa-miR-200c TCMB-201 D12 22.54 21.85 21.81 21.83 0.03 
hsa-miR-100 TCMB-201 E1 21.86 21.28 21.23 21.26 0.04 
hsa-miR-10b TCMB-201 E2 22.68 21.85 21.83 21.84 0.01 
hsa-miR-155 TCMB-201 E3 22.02 21.38 21.48 21.43 0.07 
hsa-miR-1 TCMB-201 E4 22.22 21.49 21.52 21.51 0.02 
hsa-miR-363 TCMB-201 E5 22.18 21.19 21.36 21.28 0.12 
hsa-miR-150 TCMB-201 E6 22.56 21.80 21.85 21.83 0.04 
hsa-let-7i TCMB-201 E7 22.92 22.00 21.96 21.98 0.03 
hsa-miR-27b TCMB-201 E8 22.72 21.93 21.93 21.93 0.00 
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Graph 7: Graph of transcriptiome array showing mir1 a negative regulator 
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The qPCR transcription array I performed in triplicates (as shown in the table 5 and 6) 
produced potential candidate microRNAs that regulated plexin B1 expression. The next 
step is to verify the result. It was shown that microRNA 1 significantly negatively 
regulated plexin B1 a new finding that was hitherto unknown.  This is shown graphically 
in graph 7 above.  
 
 
 
Discussion 
 
This section of my study has revealed a potential candidate microRNA. MicroRNA 1 
appears to be a negative regulator of plexin B1 expression as shown clearly on the 
graph image above. It is also followed closely by mir 206, mir 29a and as suggested by 
Qiang et al mir214* although none these other microRNAs reach a significant level of 
regulation (Qiang et al., 2011). The candidates miRNAs used in this array are known to 
be cancer specific microRNAs. Expression of some miRNAs resulted in an increase I 
plexinB1 mRNA levels. This is most likely to be due to an indirect mechanism of 
expression control. These miRNAs may, for example reduce the expression of a 
plexinB1 inhibitor. 
  
The study by Hudson et al in 2012 strongly suggests a role of microRNA 1 as a tumour 
suppressor in prostate cancer(Hudson et al., 2012). They showed that this microRNA 
prevents invasive properties in cancer cells and also the formation of filipodia. They 
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reveal that microRNA 1 is linked to prostate cancer metastasis and that there is an 
inverse relationship with reduction in its expression in metastatic tissue and that it 
directly and indirectly suppresses oncogenes involved in prostate cancer. It is therefore 
likely that microRNA 1 is a potential regulator of plexin B1 as shown by my trascriptome 
array studies.  
 
The full list of the 90 cancer specific microRNAs used in the 96 well transcriptome array 
are listed in the appendix section. 
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Chapter 6 
 
 
 
Verification of the effect of candidate 
microRNAs on plexin B1 expression
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Introduction 
The increased levels of plexin B1 in primary and metastatic prostate tissue when 
compared to normal tissue, as reported by our group, suggests a link between plexin B1 
and prostate cancer metastasis (Wong et al., 2007). There have been several studies 
linking microRNAs specifically to prostate metastasis. What would be of interest is if any 
of these microRNAs may regulate plexin B1 expression. Aberrant miRNA control of 
plexinB1 expression could be one of the mechanisms by which plexinB1 is 
overexpressed in cancer. MicroRNA 1 has been linked to prostate cancer metastasis as 
shown by Hudson et al(Hudson et al., 2012), and the results of my transcriptome array 
studies in the previous chapter is in keeping with their findings. Some other microRNAs 
suggested to be linked to prostate cancer metastasis are mir221, mir154 and mir379 
(Kneitz et al., 2014, Gururajan et al., 2014). I intended to discover whether any other 
microRNA also targeted plexin B1.  
 
The next set of experiments were aimed at validating the findings of my results from the 
transcriptrome array and to find other potential regulating microRNAs.  I wished to 
determine if the expression levels of plexin B1 mRNA and protein had a direct 
correlation with the candidate microRNAs. I decided to investigate microRNA 1 (mir1) 
due to the transcriptome array results. I also chose microRNA 214 (mir214) because it 
was a regulator of plexin B1 in my transcriptome array studies, albeit not a statistically 
significant one, it has also been shown to negatively regulate plexin B1 in cervical 
cancer cells in the study by Qiang et al (Qiang et al., 2011). Interestingly in the 
transcriptome array study it can be seen that mir214 both positively and negatively 
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regulates plexin B1 depending on the variant of mir214. I chose to study the positive 
regulator mir214-3p (accenssion number MIMAT0000271). I expected mir214-3p to 
potentially increase the expression of plexin B1 by an indirect mechanism as suggested 
by the transcriptome array results as seen in figure 28 of the previous chapter . I also 
analysed the online microRNA databases ( mirBASE, mirWALK, MiRanda) to assess 
microRNA candidates that are predicted to regulate plexin B1(mirwalk, 2014, Mirbase) 
to look for potential miRNA binding sites. The above analysis revealed three microRNA 
candidates these microRNAs were mir320d, mir199a-5p, mir101-3p. The databases 
yielded quite a few microRNA candidates but these three were the most frequent 
occuring matches across the databases.  Interestingly mir1 did not come up as a direct 
candidate microRNA regulator of plexin B1 on the databases and this may be perhaps 
because there are no obvious binding sites on the 3’UTR of plexin B1 for the  known 
seed region of mir1. Not withstanding based on my transcriptome experiments which 
revealed a significant negatively inhibitng role for mir1 on triplicate experiments I 
decided to investigate mir1 as well as mir214. I also made use of scramble short 
stranded microRNAs, from mirVana that served as a  negative control, which I chose to 
call ‘mirVana’ for simplicity of terminology. I then obtained these microRNA candidates, 
the five of them in the form of microRNA mimics from Quiagen miScript miRNA mimics 
for my investigations. 
 
I created the vector-construct (Luc-3’UTR) in which the 3’UTR is placed downstream of 
the luciferase gene (chapter 4) in order to investigate whether there were direct 
interactions between my candidate microRNAs and plexin B1 3’UTR by cotransfecting 
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the microRNA and the Luc-3’UTR and monitoring luciferase activity. I assessed the 
luciferase acitvity in these contransfections by using the luminometer  Walac 1420. If 
the luciferase activity reduced in comparison to controls, then it meant the candidate 
microRNA halted the translation of the luciferase reporter mRNA implying that the 
binding of the miRNA to the 3’UTR of plexinB1 controls expression of the plexinB1 
gene.  
 
I then performed transfection control studies using the live imaging recording technique 
of an incucyte imaging system to assess the real time effect of transfection. This was in 
order to optimise the next set of transfection experiments which lacked the luciferase 
marker of the above co-transfection studies. 
 
I then performed western blot experiments. These experiments were aimed at 
investigating whether the expression levels of plexin B1 protein varied depending on 
different candidate microRNAs.  I assessed the levels of plexin B1 protein after I had 
transfected the different candidate microRNAs into the prostate cancer cell lines PC3 
and LNCaP.  
 
I then assessed the levels of plexin B1 mRNA levels by performing quantitative 
Polymerase Chain Reaction (qPCR) after transfection with the candidate microRNAs. 
This was to assess whether certain microRNAs had a greater effect than others on the 
expression level of plexin B1 mRNA.  
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In terms of the cancer cell lines for the transfection and also the co-transfection studies,  
I used DU145,PC3 and LNCaP cell lines. LNCaP cell lines tend not to adhere as well to 
the surface of a well as the others but as shown in the results of the qPCR studies in the 
third chapter they have the highest level of endogenous plexin B1 and therefore were of  
interest. I aimed to discover if microRNA transfection affected plexin B1 expression 
levels differently in PC3 cells which have the lowest levels endogenous plexin B1 
compared to LNCaP cells.   
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Results 
This section is divided into two parts 
1. the results of the miRNA LUC-3’UTR  co-transfection experiment.  
2. The assessment of the efficacy of transfection with the transfection control 
investigation, the assessment of plexin B1 mRNA by qPCR, and plexin B1 
protein expression levels by Western blotting. 
 
1. The results of candidate miRNA co-transfection with pmirGlo LUC-plexinB1-
3’UTR reporter vector into cell lines 
The candidate microRNAs were co-transfected with the vector-construct into prostate 
cancer cell lines PC3 and DU145. Optimisation experiments were performed initially to 
determine the best conditions for co-transfection. The co-transfection experiment was 
performed following the Attractene transfection reagent handbook by Qiagen as well as 
searching the Qiagen transfection database protocol which I used to create specific 
protocols for the 96 well plate of the two cell lines (Qiagen). Qiagen recommended the 
attractene reagent for co-transfections while HiPerfect transfection reagent was 
recommended for transfection of single miRNAs. I used the Wallac 1420 luminometer to 
evaluate the luminescence of the cotransfection experiments. I co-transfected the vector 
construct LUC-3’UTR with the microRNAs,  or with the scrambled microRNA, and 
compared this with the transfection of the vector construct LUC-3’UTR on its own.  
 
The co-transfections were successful following optimisation of the protocols.  In my 
optimising experiments I initially transfected using the fast forward protocol which 
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involved plating and transfection on the same day. I discovered that the traditional 
protocol involving plating the cells for a period of 24hours before transfection the next 
day produced better results and so continued with the traditional approach in the main 
experiments. I found transfection most effective in the PC3 cells compared to DU145 
cells and so I decided to focus on the contransfection experiments using the PC3 cell 
line.  
1a: Mir 214-3p contransfections: 
 The graphs below contain the result breakdown of the co-transfection investigations for 
mir214-3p. Graph 8 shows the results of co-transfection of LUC-3’UTR construct or 
LUC-control construct with or without mir214-3p or scrambled miRNA into DU145 cells. 
Transfection of mir 214-3p decreased luciferase expression levels of LUC-3’UTR 
construct in comparison with co-transfection of the construct with scrambled miRNA or 
no miRNA co-transfection. This was also shown in PC3 cells, where I performed the 
cotransfection on three separate occasions  as shown in graph 9 below.
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Graph 8: Co-transfection involving mir214-3p in DU145 cell line 
the graph shows DU145 cells that have had; mir 214-3p co transfected with vector construct (IN + 214-
3p), or with control vector (CN+ 214-3p). DU145 cells co transfected with scrambled mirRNA and vector 
construct (IN+ mirVana), or with scrambled mirRNA with control vector (CN+ mirVana), or  DU145 
transfected alone with vector construct (IN) or vector control (CN) 
 
Graph 9: Average of Co-transfections in PC3 cells 
The graph shows the average of three separate co transfection experiments ( each of the separate 
experiment were also done in triplicates) in PC3 cells.  The cells were either transfected with vector 
construct and mir 214-3p (IN+ mir214-3p), vector construct and scramble miRNA(IN+ mirVana), or vector 
construct alone(IN). 
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There is a dose response when transfection is performed with the mir 214-3p. This is 
shown in the graph 10 below. I found that increasing doses of mir 214-3p reduced the 
expression of plexin B1 luciferase proportionally. There is a dose response of reduced 
luminescence as I increased the concentration of mir214-3p. In contrast, increased 
concentration of control scrambled miRNA had no effect on LUC-3’UTR luciferase 
activity. This suggests that mir214-3p has targeted the 3’UTR of plexin B1 and with 
increasing dosage there was more mir 214-3p available to prevent further translation of 
the luciferase mRNA. Thus mir 214-3p negatively regulated plexin B1 3’UTR. 
 
Graph 10: Dose response to increasing concentration of mir214-3p in PC3 cells 
The graph shows PC3 cells transfected with vector construct alone (IN), or along with mir 214-3p ( IN+ 
MIR 214-3p) or with scrambled miRNA ( IN+mirVana).  Increasing concetrations of microRNAs were 
abbreviated in to X2- for double concetration and  X4 for 4 times the concentration. 
 
 
The next graph 11 shows the co-transfection of mir214 and LUC-3’UTR vector in 
DU145 cells. In theory there should be no difference as the cell lines in these co-
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transfection experiments act as hosts for the interaction of both transfected substances 
but it appears that in DU145 cells there was no dose response in contrast to what was 
observed in PC3 cell lines it is important to note that the luminescence values of the 
DU145 experiments are much smaller so perhaps the response would be harder to 
detect with reduced luminescence overall. A possible explanation for this reduced 
luminescence was the fact that the measurement of the luminescence by the 
luminometer was done first in the PC3 cells before the DU145 and some decay of the 
luciferase may have occurred in the interval before the measurement was taken.     
 
Graph 11: No dose response to increasing concentration of mir214-3p in DU145 
The graph shows DU145 cells transfected with vector construct alone (IN), or along with mir 214-3p ( IN+ 
MIR 214-3p) or with scrambled miRNA ( IN+mirVana).  Increasing concetrations of microRNAs were 
abbreviated in to X2- for double concetration and  X4 for 4 times the concentration. 
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1b: Transfection with other microRNAs: 
I then went on to carry out cotransfection experiments involving the other candidate 
microRNAs. The results were varied as shown by the graphs below. I found that mir 
199a-5p also negatively regulates the expression of plexin B1, while the other 
microRNAs; mir 1, mir 101 and mir320d did not.     
 
 
 
Graph 12: Co-transfections of microRNAs in PC3 cells 
The graphs below show the effect of co transfection of the microRNAs into the PC3 cell lines. 12a shows 
transfection with vector construct alone (IN), or along with mir 199-5p ( IN+ MIR 199-5p) or with 
scrambled miRNA ( IN+mirVana). 12b shows transfection with vector construct alone (IN), or along with 
mir 1 ( IN+ mir 1) or with scrambled miRNA ( IN+mirVana). 12c shows transfection with vector construct 
alone (IN), or along with mir 101 ( IN+ mir 101) or with scrambled miRNA ( IN+mirVana). 12d shows 
transfection with vector construct alone (IN), or along with mir 320d ( IN+ mir 320d) or with scrambled 
miRNA ( IN+mirVana). 
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12b 
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To further verify the findings from my co transfection experiments I carried out 
transfection reactions assessing the mRNA and protein expression levels of plexin B1 
as shoewn below in section 2.  
 
2. The results of miRNA transfection alone into cell lines  
 
2a: Transfection control experiments 
I initially carried out transfection control investigations to confirm that the transfection 
took place successfully. A siRNA (the Allstar Hs Cell Death control) that is lethal to cells 
in which it is expressed was used and cell death monitored using the Incucyte Imaging 
system. The results revealed effective transfection using siRNA control Allstar Hs Cell 
Death control (5nmol) following the Qiagen transfection protocol with HiPerfect reagent. 
The imaging system was set to take images every 4 hours for a duration of 184 hours to 
assess changes in each well. Cell death occurred in all wells transfected with two 
different concentrations of SiRNA in almost identical pattern while the control cells that 
were transfected with water or PBS remained fully viable. See graphs below
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Graph 13: Transfection control of SiRNAs in PC3 cells 
13a shows transfection of PC3 cells with 6ul SiRNA concentration; 13b shows transfection of PC3 cells 
with 12ul SiRNA concentration; 13c shows transfection of PC3 cells with PBS as control; and 13d shows 
transfection of PC3 cells with water as control 
13a 
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13b 
 
13c 
143 
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2b: Transfection of candidate microRNA into cell lines and assessment of plexin B1 
mRNA expression by qRT-PCR 
I then went on to transfect PC3 cells with the candidate microRNAs to confirm the 
interacts noted in section one in a different cell line.These experiments were designed 
to assess the effect of expression of the miRNAs on the levels of endogenous plexinB1 
in prostate cancer cell lines and to determine if the candidate miRNAs had an indirect 
effect on plexinB1 expression levels in addition to their direct effects 9ie by binding to 
the 3’UTR of plexinB1). Indirect effects on the mRNA levels of plexinB1 would not be 
detected by the LUC-3’UTR reporter construct studies. MiRNAs have been shown to 
both inhibit mRNA translation into protein or to result in degradation of the mRNA, 
depending on cellular context.  Both mechanisms would be detected in the experiments 
using the reporter construct and luciferase activity. However only the miRNA-mediated 
mechanism resulting in mRNA degradation would be detected by monitoring changes in 
mRNA levels. 
 
Transfection reactions were as per the Qiagen transfection protocol created from the 
protocol database using HiPerfect transfection reagent. The RNA was then extracted 
and after first strand cDNA sythesis was done using invitrogen superscript III protocol, 
qPCR performed as described in the methology in the second chapter. 
I performed three sets of experiments and in each experiment carried out duplicate 
reactions in each experiment.The results of the average of these experiments are 
shown in the graph below.
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Graph 14:  The average of 3 separate plexin B1 mRNA expression levels  as assessed 
by qPCR after transfection of microRNAs in PC3 cells 
The graph shows the average of the relative expression levels of plexin B1 mRNA after transfection with 
four microRNAs and two controls water and the scrambled microRNA ( mirVana) in PC3 cells as 
assessed by qRT-PCR 
 
The qRT-PCR results showed a down regulation of plexin B1 in mir 199a-5p, mir 1 and 
to a lesser extent mir 214-3p compared to water and the scrambled microRNA mirVana.  
There was no difference between the average results of transfected mir 320d compared 
to water and scrambled microRNA. The downward regulation of plexin B1 expression by 
microRNA 1 in keeping with the transcriptome array results. Mir 199a-5p appears to 
have a greater negative regulatory effect than mir1. Either miRNA 1 or 199a-5p may 
have may have clinical utility if their effects are verified and it is considered as a 
therapeutic option. 
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2c: Transfection of candidate microRNA into cell lines and assessment of plexin B1 
protein expression by western blotting 
In order to clarify the findings from the qRT-PCR and co-transfection studies I   
performed another set of transfection investigations this time assessing the plexin B1 
protein expression levels. I used the LNCaP cells as hosts for transfections in these set 
of experiments as they have the higher amounts of endogenous plexin B1. I repeated 
this test until I obtained 3 satisfactory Western blots, as seen below in figure 24.  
 
Figure 24:  Western blots of plexin B1 protein after transfection of microRNAs 
24a and 24b show images of western blottings of LNCaP cells transfected with a series of microRNAs 
with plexin B1 protein on the upper section and actin control on the lower section of each consecutive 
image.  
24a 
 
24b 
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I used the ImageJ programme to measure the intesity of plexin B1 Western blot bands 
relative to actin control for each of the microRNAs transfected. This was to obtain a 
more accurate value of the level of plexin B1 protein expressed.  It involved measuring 
the intensity of both plexin and actin bands; the ratio of the intensity of plexin to actin 
bands was then calculated, I then normalised this ratio with the control. I found that 
there was a variation in the values depending on the transfected microRNA. I took the 
average of the best three Western blots studies to further increase the overall accuracy 
of the Western blots as shown in the graphs below.   
 
Graph 15:  The average of 3 separate plexin B1 protein expression levels by Western 
blotting after transfection of microRNAs in PC3 cells 
The graph shows the average of the plexin B1 protein levels after transfection of microRNAs in LNCaP 
cells as obtained by Western blotting and measured using the ImageJ software. 
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The results of the Western blot studies as shown by graph 15 suggests mir 320d is the 
only negative regulator of plexin B1 protein. It is difficult to draw any conclusions 
because my Western blots are at best semi quantitative and not accurate either the 
qRT-PCR used for the plexin B1 mRNA analysis or the luciferase reporter construct and 
luminometer used for the co transfection.  
 
 
 
Discussion 
The results of this section does suggest that plexin B1 expression may be regulated by 
microRNAs. I investigated five different microRNAs that according to electronic 
databases and my previous transcriptome results potentially regulated plexin B1 levels. 
The luciferase-reporter cotransfection studies revealed that plexin B1 was negatively 
regulated by miR 214-3p and it was a dose response relationship. I was able to assess 
the effect of mir 214-3p more accurately by performing study in triplicates. As this co-
transfection study assesses the control of the reporter gene by the 3’UTR of plexinB1, 
resulting from a direct interaction of the microRNA with the 3’UTR section of plexin B1. 
It would appear that mir 214-3p is a direct regulator of plexin B1. The other microRNAs 
to show a negative regulatory effect on plexin B1 in this LUC-3”UTR miRNA co-
transfection study was mir 199a-5p although this was a single experiment not a triplicate 
study as with mir 214-3p.  It is important to note at this point that according to my 
transcriptome array studies, which measure the effect of miRNAs on endogenous 
plexinB1 levels in Hela cells, mir 214-3p was predicted to positively regulate plexin B1.  
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MiRNA-214-3p may have a dual effect on plexinB1 expression – it may act indirectly to 
enhance plexinB1 expression (as shown in the transcriptome studies in Hela and in 
PC3 cells) and to directly inhibit expression (as shown in the LUC-3’UTR reporter gene 
studies), and the net effect is due to a balance between these two effects. The other 
microRNAs, mir 101, mir 320d and mir 1 did not negatively regulate plexin B1, but again 
these were single experiments. It would not be surprising if these other microRNAs 
either bind to other regions of the plexinB1 mRNA not represented in the LUC-3’UTR 
construct, or were indirect regulators of plexinB1 expression (for example by inhibiting 
an inhibitor of plexinB1 expression).  
 
The next set of studies, the transfection control studies, showed very clearly that 
transfections occurred with the set of reagents being used following the prescribed 
protocol. Armed with this information I went on to transfect the candidate microRNAs 
and assessed the level of plexin B1 mRNA using qRT-PCR and protein levels using 
western blotting.  The qPCR results confirmed the transcriptome experiments showing 
the negative regulatory effect of miR 1.  Mir 214-3p was also a negative regulator of 
plexin B1 mRNA like the co transfection studies but again unlike the transcriptome array 
results.  Finally the mir 199a-5p had the largest negative regulator effect, and this 
negative regulator effect was again in keeping with the co transfection studies. The mir 
320d did was not found to negatively regulate plexin B1 mRNA in the qRT-PCR studies. 
 
The results of the Western blots were at variance with the other studies and this is 
possibly due to a variety of reasons. Western blots are known to have many short-
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comings (Taylor et al., 2013, Murphy and Lamb, 2013). Although I optimised my 
reactions and used the right controls and antibodies there were still a varied level of 
image quality. The Western blot though being practiced for many years still requires a 
high level of expertise. I feel that with further experiments the results may be different. 
 
Another point of caution in the overall picture of this chapter is that on reflection I did not 
use a positive control such as mir 214-5p. Mir214-5p unlike mir 214-3p, has been 
shown to negatively regulate plexin B1 in cervical cancer cells as reported by Qiang 
(Qiang et al., 2011). To obtain a more accurate reading a known negative regulator 
such as mir214-5p should have been used to validate the results of my studies. 
Therefore a repeat of the studies in this chapter including mir 214-5p is a suggestion for 
future studies especially as it was also found to be a negative regulator in my 
transcriptome studies in the fifth chapter.
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Chapter 7 
 
 
 
 
Discussion 
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Discussion 
This section is divided into the following sections 
I. Review and significance of this study 
II. Future work 
 
Review and significance of this study 
Plexin B1 is the main receptor for Semphorin 4 D and this receptor- ligand complex 
have important functions in the body from the development of the nervous system 
where they act as guidance cues to developing neurones, to the immune system where 
it activates B cells and semaphorin 4D is also known as CD100 an important cell 
surface marker. While the role of plexin B1 in prostate cancer has become clearer with 
the increased expression of plexin B1 protein and plexin B1 mutations in prostate 
cancer the reason for the upregulation of plexin B1 has yet to be elucidated.  
 
I therefore set out to discover the possible mechanism for this increased expression of 
plexin B1 to investigate what regulatory mechanisms may exist that leads to this 
upregulation in its expression. I hypothesized that a possible mechanism of the 
regulation of plexin B1 expression is due to microRNAs, the ubiquitous small RNA 
molecules that were discovered in the early 1990s and have grown in significance as 
the scope and importance of their functions have been revealed. I hypothesized that 
plexin B1 was upregulated either due to a lack of binding sites to the regulating 
microRNAs or a lack of these microRNAs themselves. 
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To set out to answer my questions I first carried out experiment in chapter 3 to confirm 
the existence of plexin B1 in a chosen set of cancer cell lines. I was able to show that 
plexin B1 was expressed in all the cell lines including PC3/27, DU145/71, Yusik10, 
GCT27/75, 22RV1/5,1542NP/51 and LNCaP/73 by RT-PCR and I was also able to 
accurately quantify the relative levels of expression of plexin B1 in these cell lines using 
qRT-PCR. I found that plexin B1 is most abundant in 1542CP cells. LNCaP-LN3, a 
derivative of LNCaP selected by serial transplantation of metastases in mice, had 
increased levels of plexinB1 mRNA relative LNCaP, suggesting that the increase in 
expression may be associated with metastasis. LNCaP cells specifically LNCaP LN3. It 
is least expressed in PC3 cells. I hypothesize that the varying levels of expression as 
seen on qRT-PCR may be linked to the metastatic origins of the cell lines with LNCaP 
cell lines being derived from lymph node metastases and PC3 from bone metastases. 
  
I then went on to investigate the variants of plexin B1 to search for variants of that 
lacked binding sites to microRNAs. As microRNAs bind mainly to the 3’UTR of mRNA I 
performed 3’RACE experiments that did not reveal any plexin B1 variants lacking in the 
3’UTR section. Thus I did not find any variants that would be resistant to complementary 
binding effects of microRNAs that possibly regulate plexin B1 expression through that 
common mechanism. This is not to say plexin B1 cannot be regulated by binding to 
other sites along the main regions of its mRNA or even indirectly regulated. In terms of 
other possible binding sites for microRNAs there are two variants of plexin B1 shown by 
the NCBI database to lack exon 11, variant R and the truncated variant of plexin B1. I 
was able to show the existence of these two by performing RT-PCR using primers for 
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exon 11 of plexin B1. Of the two variants the truncated variant has been shown to exist 
in literature by Tamagnone (Tamagnone et al., 1999) while this I believe is the first time 
that variant R was identified through invitro analysis outside of the online databases. 
The NCBI attributes the Tamagnone paper with showing variant R but on review of the 
paper only the truncated variant is mentioned. This finding has significance not just in 
terms of a binding site to microRNAs using the main body of mRNA route but also the 
fact that this variant may have altered functions that needs to be explored. The 
truncated variant is predicted to produce a small extracellular protein with a sema 
domain and a novel 52 amino acid sequence. This is predicted to bind to sema4D and 
full length plexinB1 protein and could act as a domininant negative inhibitor of plexin 
signaling. The R variant has a mucin-like domain missing and is predicted to have 
altered function. All cell lines tested expressed both variants with a much higher 
abundance of the truncated version than the variant R at the mRNA level. 
 
I then went on as stated in the fourth chapter to create a plasmid vector construct 
containing the 3’UTR of plexin B1 which I would then use to confirm that this section of 
plexin B1 is active through transfection studies by comparing the vector construct 
containing the 3”UTR of plexin B1 to control vector. Lower levels of reporter gene 
activity was seen in cells transfected with the LUC-3’UTR construct compared to the 
LUC-control vector, showing that the 3’UTR exerts some repression on reporter gene 
expression. I then performed transcriptome array experiments, which revealed plexin B1 
mRNA was negatively regulated by mir 1 and to a less significant level by mir 214-5p as 
well as mir 206. I selected a number of candidate miRNAs from these studies and from 
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analysis of potential binding sites in the DNA sequence of the 3’UTR of plexinB1 for 
further analysis. I transfected 5 candidate microRNAs together with the LUC-3’UTR  
vector construct and assessed the level of reporter gene expression using a 
luminometer to detect the luciferase reporter activity. I also performed qRT-PCR and 
Western blots to determine the effect of the candidate miRNA on expression of 
endogenous plexinB1 mRNA and protein in prostate cancer cells.  
 
In summary, my results indicate three potential miRNA candidates for regulation of 
plexinB1 expression: 
 
MiRNA199a negatively regulated expression of the LUC-3’UTR reporter, suggesting a 
direct effect on plexinB1 gene expression, and decreased endogenous levels of 
plexinB1 mRNA in prostate cancer cells. It had little effect in the transcriptome studies 
which assessed endogenous levels of plexinB1 in Hela cells. MiRNA199a may therefore 
have both a direct effect of plexinB1 expression and indirect effects which are cell 
context specific. 
MiRNA 1 repressed endogenous expression of plexinB1 in both Hela and PC3 cells, but 
had  little effect on the LUC-3’UTR reporter assay. Hence miRNA 1  may have indirect 
effects on endogenous plexinB1 expression but no direct effect via binding to the 
3’UTR. This is consistent with the lack of obvious miRNA binding sites in the 3’UTR of 
plexinB1. Alternatively the miRNA 1 may bind to a region of the plexinB1 mRNA not 
cloned into the LUC-3’UTR vector used in these experiments. 
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MiRNA 214-3p positively regulated expression of plexinB1 in Hela cells, although the 
increase was not significant, and like miRNA 199a, negatively regulated LUC- 3’UTR  
construct and endogenous plexinB1 in PC3 cells. Mir 214-3p may, like miRNA 199a, 
have direct effects on plexinB1 expression by binding to the 3’UTR of plexinB1, as well 
as indirect effects that are specific to the type of cell. 
 
To make any firm conclusions there is a need for a positive control to validation of my 
transfection work, I suggest mir 214-5p again as explained in chapter 6.   
 
Future work 
There is a lot of scope for further work in this study. Once the results are validated, the 
next stage should be tissue studies evaluating the levels of these candidate microRNAs 
relative to plexin B1 looking especially for an inverse relationship. I expect an inverse 
realtionship, with plexin B1 levels increasing with distance metastasis compared to the 
primary prostate tumour, while the candidate microRNAs levels should decrease in 
distant metastasis compared to the primary prostate tumour. This would be assessed by 
Insitu hybridization for the microRNA levels in tissue and immunohistochemistry for the 
plexin B1 protein levels in tissue. The LUC-3’UTR experiments could be validated by 
mutation of the postulated miRNA binding sites in the construct. Further evidence for 
the role of the candidate miRNAs in regulation of plexinB1 mRNA expression could be 
gained by expressing anti-MIRS into PC3 cells; this is predicted to increase expression 
of plexinB1. 
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If the results are in keeping with my preliminary findings then the obvious next step 
would be to test out the candidate microRNAs for the therapeutic potential in the subset 
of prostate cancer associated with plexin B1. Priliminary mice studies being carried out 
by our group, which are yet to be published suggest that plexin B1 also affects primary 
prostate cancer formation in mouse models of prostate cancer as mice deficient of 
plexin B1 in their prostate show delayed development of primary tumours as compared 
to the same mouse models with the plexin B1 gene intact (personal communication).  
This adds further impetus to discovering pharmaceutical agents that can block plexin B1 
in the prostate. My hope is that microRNAs could be one of these therapeutic agents 
and perhaps some of the candidate microRNAs I have identified.
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Appendix 
 
An example is shown below of the nucleotide sequences of the ~800bp, ~250bp and 
~200bp bands from the cell line LNCaP. Electropherograms are shown below. 
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The full list of the 90 cancer specific microRNAs used in the 96 well transcriptome array 
 
Position Symbol Description 
A01 hsa-let-7a MIMAT0000062 
A02 hsa-miR-133b MIMAT0000770 
A03 hsa-miR-122 MIMAT0000421 
A04 hsa-miR-20b MIMAT0001413 
A05 hsa-miR-335 MIMAT0000765 
A06 hsa-miR-196a MIMAT0000226 
A07 hsa-miR-125a-5p MIMAT0000443 
A08 hsa-miR-142-5p MIMAT0000433 
A09 hsa-miR-96 MIMAT0000095 
A10 hsa-miR-222 MIMAT0000279 
A11 hsa-miR-148b MIMAT0000759 
A12 hsa-miR-92a MIMAT0000092 
B01 hsa-miR-184 MIMAT0000454 
B02 hsa-miR-214 MIMAT0000271 
B03 hsa-miR-15a MIMAT0000068 
B04 hsa-miR-18b MIMAT0001412 
B05 hsa-miR-378 MIMAT0000732 
B06 hsa-let-7b MIMAT0000063 
B07 hsa-miR-205 MIMAT0000266 
B08 hsa-miR-181a MIMAT0000256 
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B09 hsa-miR-130a MIMAT0000425 
B10 hsa-miR-199a-3p MIMAT0000232 
B11 hsa-miR-140-5p MIMAT0000431 
B12 hsa-miR-20a MIMAT0000075 
C01 hsa-miR-146b-5p MIMAT0002809 
C02 hsa-miR-132 MIMAT0000426 
C03 hsa-miR-193b MIMAT0002819 
C04 hsa-miR-183 MIMAT0000261 
C05 hsa-miR-34c-5p MIMAT0000686 
C06 hsa-miR-30c MIMAT0000244 
C07 hsa-miR-148a MIMAT0000243 
C08 hsa-miR-134 MIMAT0000447 
C09 hsa-let-7g MIMAT0000414 
C10 hsa-miR-138 MIMAT0000430 
C11 hsa-miR-373 MIMAT0000726 
C12 hsa-let-7c MIMAT0000064 
D01 hsa-let-7e MIMAT0000066 
D02 hsa-miR-218 MIMAT0000275 
D03 hsa-miR-29b MIMAT0000100 
D04 hsa-miR-146a MIMAT0000449 
D05 hsa-miR-212 MIMAT0000269 
D06 hsa-miR-135b MIMAT0000758 
D07 hsa-miR-206 MIMAT0000462 
D08 hsa-miR-124 MIMAT0000422 
D09 hsa-miR-21 MIMAT0000076 
D10 hsa-miR-181d MIMAT0002821 
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D11 hsa-miR-301a MIMAT0000688 
D12 hsa-miR-200c MIMAT0000617 
E01 hsa-miR-100 MIMAT0000098 
E02 hsa-miR-10b MIMAT0000254 
E03 hsa-miR-155 MIMAT0000646 
E04 hsa-miR-1 MIMAT0000416 
E05 hsa-miR-363 MIMAT0000707 
E06 hsa-miR-150 MIMAT0000451 
E07 hsa-let-7i MIMAT0000415 
E08 hsa-miR-27b MIMAT0000419 
E09 hsa-miR-7 MIMAT0000252 
E10 hsa-miR-127-5p MIMAT0004604 
E11 hsa-miR-29a MIMAT0000086 
E12 hsa-miR-191 MIMAT0000440 
F01 hsa-let-7d MIMAT0000065 
F02 hsa-miR-9 MIMAT0000441 
F03 hsa-let-7f MIMAT0000067 
F04 hsa-miR-10a MIMAT0000253 
F05 hsa-miR-181b MIMAT0000257 
F06 hsa-miR-15b MIMAT0000417 
F07 hsa-miR-16 MIMAT0000069 
F08 hsa-miR-210 MIMAT0000267 
F09 hsa-miR-17 MIMAT0000070 
F10 hsa-miR-98 MIMAT0000096 
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F11 hsa-miR-34a MIMAT0000255 
F12 hsa-miR-25 MIMAT0000081 
G01 hsa-miR-144 MIMAT0000436 
G02 hsa-miR-128 MIMAT0000424 
G03 hsa-miR-143 MIMAT0000435 
G04 hsa-miR-215 MIMAT0000272 
G05 hsa-miR-19a MIMAT0000073 
G06 hsa-miR-193a-5p MIMAT0004614 
G07 hsa-miR-18a MIMAT0000072 
G08 hsa-miR-125b MIMAT0000423 
G09 hsa-miR-126 MIMAT0000445 
G10 hsa-miR-27a MIMAT0000084 
G11 hsa-miR-372 MIMAT0000724 
G12 hsa-miR-149 MIMAT0000450 
H01 hsa-miR-23b MIMAT0000418 
H02 hsa-miR-203 MIMAT0000264 
H03 hsa-miR-32 MIMAT0000090 
H04 hsa-miR-181c MIMAT0000258 
H05 hsa-miR-20b* MIMAT0004752 
H06 hsa-miR-214* MIMAT0004564 
H07 VTC Negative Control 
H08 VTC Negative Control 
H09 VTC Negative Control 
H10 VTC Negative Control 
H11 PPC SA_00104 
H12 PPC SA_00104 
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